Podcasts about compass pathways

Shownotes   Exactly what Internal Family Systems therapy is The actual mechanism that creates the most profound level of healing Psychedelics as a loving catalyst to know ourselves more The truth about psychedelic stigma Why it's important to prepare your set and setting with psychedelics The difference between doses of psilocybin   Bio   Nick Brüss, EdD, LMFT, is a leading licensed psychedelic therapist, researcher and educator who is passionate about inspiring and helping people heal, grow and live creative lives. He's pioneering treatments and programs that harness the synergistic power of combining psychedelic medicine with cutting edge therapy and coaching.    Dr. Brüss was a clinical researcher and supervisor on the ground breaking FDA Phase III clinical trial of MDMA-assisted therapy for PTSD sponsored by MAPS, and is currently a lead therapist on the Phase III Psilocybin therapy study for Treatment Resistant Depression sponsored by Compass Pathways.    In private practice, he specializes in concierge ketamine-assisted and Internal Family Systems (IFS) therapy. He trains nationally and speaks internationally on psychedelic-assisted therapy safety and efficacy, and is a co-founder of the Psychedelic Coalition for Health, a psychedelic medicine education and training platform.    Dr. Brüss is also a Certified Mindfulness Facilitator through UCLA's Mindful Awareness Research Center at the Semel Institute for Neuroscience and Human Behavior, and a certified teacher of both Mindful Self-Compassion, and the Compassion Cultivation Training through the Center for Compassion, Altruism Research and Education at Stanford University School of Medicine.   Find more about Dr. Brüss' work at www.apracticeoffreedom.com and connect with him on LinkedIn and Instagram. Timestamps   00:01:14 - Guest introduction 00:02:20 - How Layla and Dr. Brüss originally connected 00:04:51 - Sign up for Layla's newsletter at LaylaMartin.com 00:06:51 - The first time Layla experienced her own somatic avoidance 00:11:14 - Humans are so beautiful when they don't have so much pain 00:13:52 - Dr. Brüss explains what Internal Family Systems therapy is 00:19:24 - Unlock your deepest passion inside The Tantric Mastermind for Couples 00:20:06 - Discover your most masculine confidence and presence with Men's Sexual Mastery 00:21:12 - Dr. Brüss introduces listeners to MAPS 00:24:36 - The actual mechanism that creates this profound level of healing 00:27:19 - Layla shares about her experiences with MDMA 00:30:43 - How IFS integrates with felt-sense experience 00:32:30 - How intellectually “getting” something isn't the same as being “in” it 00:36:33 - We don't realize how much power we actually have 00:38:44 - Discover MOOD™ Sex Magic 00:42:48 - How psychedelics can be a loving catalyst to know ourselves more 00:44:28 - Layla shares her experience with psychedelics 00:47:22 - Dr. Brüss and Layla drink MOOD Sex Magic 00:55:28 - Psychedelic stigma was intentionally created 00:57:02 - The war on disconnection 00:57:27 - Enhance your sensitivity and pleasure inside Crystal Pleasure 00:59:15 - Why it's important to prepare your set and setting with psychedelics 01:04:33 - Dr. Brüss shares about his first psychedelic experience 01:07:24 - The difference between doses of psilocybin 01:12:06 - How different psychedelics work on different situations 01:19:53 - Conclusion  

دکتر آهو یارا، PhD، که پیش‌تر به نام صدف لطف‌علیان شناخته می‌شد، روان‌شناس بالینی و روان‌درمانگر با استفاده از روان‌نماها است. او در حوزه پزشکی روان‌نما با نهادهایی از جمله COMPASS Pathways و دانشکده پزشکی دانشگاه جانز هاپکینز آموزش دیده است، جایی که در جلسات سیلوسایبین به‌عنوان راهنمای همکار حضور داشته است. آهو در نهادهایی مانند خدمات مشاوره و روان‌شناختی دانشگاه UCLA درباره کاربرد درمانی روان‌نماها آموزش داده است.او آموزش‌های پیشرفته‌ای در رویکردهای مبتنی بر شفقت برای بهبود دارد و مربی تایید‌شده‌ی چی‌گونگ و پرانایاما است. او برنده کمک‌هزینه‌ای از ائتلاف پزشکی روان‌نما برای کارهایش در راستای اطمینان از رعایت بهترین شیوه‌ها توسط راهنمایان و مشارکت‌کنندگان در حوزه روان‌نماها شده است. آهو مدافع خرد بومی، حقوق و حفاظت از آن است و خود را وقف بهبود بازسازی‌کننده‌ی جهان طبیعی کرده است.آهو در تهران متولد شد و تا سن ۱۳ سالگی در آنجا زندگی کرد. از آن زمان، خود را به‌عنوان یک مهاجر ایرانی در مکان‌هایی از جمله استکهلم، ونکوور، بالتیمور، نیویورک، واشنگتن دی‌سی، لس‌آنجلس و اخیراً لیسبون، پرتغال شناخته است. امید او این است که افراد فضاهای امنی برای دیده‌شدن و حمایت در داستان‌ها، آسیب‌پذیری‌ها و تاب‌آوری‌هایشان داشته باشند.برای آشنایی بیشتر با آهو یارا و کارهاش می‌تونید به وبسایت یا اینستاگرمش سر بزنید:https://bio.site/ahooyarahttps://www.instagram.com/ahooyarahttps://www.instagram.com/mehran_somahttps://www.instagram.com/ravannamacommunityhttps://www.somaretreats.org Hosted on Acast. See acast.com/privacy for more information.

In the first episode of Medical Ethics Unpacked, hosts Steve Levine, MD, and Dominic Sisti, PhD, examine the profound ethical and clinical challenges surrounding medically assisted suicide, or medical assistance in dying (MAID), for individuals with severe psychiatric conditions. Dr. Sisti, an associate professor at the University of Pennsylvania, interrogates pivotal questions central to this debate, including whether psychiatric disorders can be deemed terminal and whether individuals with such conditions possess the requisite capacity to make autonomous decisions regarding MAID. Drawing on data from jurisdictions such as Belgium and the Netherlands, he highlights critical concerns, including gender disparities, inconsistent capacity evaluations, and the societal risks of expanding access to psychiatric euthanasia without addressing structural deficiencies, such as inadequate mental health care systems or pervasive social inequities. Dr. Levine, a psychiatrist, explores the complex and dynamic nature of capacity assessments, emphasizing the episodic and often treatable trajectory of psychiatric conditions such as major depressive disorder and anorexia nervosa. He reflects on the potential for recovery facilitated by novel treatments, such as ketamine or psychedelics, juxtaposed with the limitations and gaps in current psychiatric care. Together, the hosts deliberate on the ethical implications of mandating exhaustive treatment attempts, including experimental options, before permitting MAID, balanced against the imperative to respect patient autonomy. Through a rigorous and nuanced discussion, Drs. Levine and Sisti advocate for the establishment of robust ethical frameworks, equitable practices, and comprehensive capacity evaluations. Their discourse challenges societal and professional norms, encouraging reflection on autonomy, human suffering, and the intrinsic value of life in the context of this ethically fraught issue. Relevant studies and documentation mentioned in this episode: Doernberg, Samuel N., John R. Peteet, and Scott YH Kim. "Capacity evaluations of psychiatric patients requesting assisted death in the Netherlands." Psychosomatics 57, no. 6 (2016): 556-565. Kim, Scott YH, Raymond G. De Vries, and John R. Peteet. "Euthanasia and assisted suicide of patients with psychiatric disorders in the Netherlands 2011 to 2014." JAMA psychiatry73, no. 4 (2016): 362-368. Kious, Brent M., and Margaret Battin. "Physician aid-in-dying and suicide prevention in psychiatry: A moral crisis?." The American Journal of Bioethics 19, no. 10 (2019): 29-39. Nicolini, Marie E., Scott YH Kim, Madison E. Churchill, and Chris Gastmans. "Should euthanasia and assisted suicide for psychiatric disorders be permitted? A systematic review of reasons." Psychological medicine 50, no. 8 (2020): 1241-1256. Nicolini, Marie E., Chris Gastmans, and Scott YH Kim. "Psychiatric euthanasia, suicide and the role of gender." The British Journal of Psychiatry 220, no. 1 (2022): 10-13. Sisti, Dominic, J. John Mann, and Maria A. Oquendo. "Suicidal behaviour is pathological: implications for psychiatric euthanasia." Journal of Medical Ethics (2024). Relevant disclosures for Sisti include Lykos Therapeutics and Tactogen. Relevant disclosures for include Levine include Compass Pathways. Chapters 00:00 - Introduction 00:45 - Key Issues in the Debate on Euthanasia and Mental Illness 07:25 - Clinical Perspective on Capacity and Competence 12:45 - Challenges in Evaluating Capacity in Mental Illness 19:32 - Treatment Options and the Role of Social Structures 26:35 - The Parity Between Mental and Physical Illness 31:41 - Requiring Treatment Before Considering Euthanasia 34:44 - The Complexity of Egosyntonic Psychiatric Conditions 37:52 - The Potential for "Terminal Addiction" 43:05 - The Societal Impact and Implications of Psychiatric Euthanasia

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk's weight loss drug Wegovy showed significant improvement in liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis in a Phase III trial. Bristol Myers Squibb reported strong third-quarter results, while Regeneron had mixed sales results. Eli Lilly's third-quarter miss highlights their dependency on wholesaler stocking decisions. Lexicon lost an FDA advisory committee vote, and Merck lowered its full-year sales guidance despite strong Q3 results. Compass Pathways is laying off 30% of its employees. Novartis received FDA approval for Scemblix in certain CML patients. Opportunities for job seekers are available in the biotech industry.

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Dr. Stephen Thayer, a clinical psychologist and lead trainer for psychedelic therapists at Numinus. Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-262-stephen-thayer-phd/?ref=278 Dr. Thayer shares his journey from military psychologist to psychedelic-assisted therapy specialist, discussing his personal experiences with ketamine and psilocybin. He explores the integration of psychedelics into therapy and coaching, highlighting the distinctions between these roles. Dr. Thayer emphasizes the importance of facilitator training and personal psychedelic experiences, making a compelling case for evidence-based psychedelic mental healthcare alongside ceremonial or spiritual contexts. Note: This conversation was recorded in May 2024, prior to the FDA's decision on Lykos Therapeutics' MDMA-assisted therapy clinical trial for PTSD. The recent FDA ruling, which requested additional studies, will impact some of the information discussed regarding MDMA's path to medical approval. However, we believe this episode remains valuable for its insights into the broader landscape of psychedelic therapy, practitioner training, and the ongoing evolution of the field. Enjoy! Dr. Steve Thayer, Ph.D. is a clinical psychologist who specializes in psychedelic-assisted therapy practice, training, and research. He began his career in the U.S. Air Force where he led mental health care teams, provided therapeutic and assessment services, and counseled military leadership about community mental health concerns. As an adjunct professor, Dr. Thayer has taught graduate and undergraduate courses in counseling skills, clinical psychology, and personality theory. He has served as the lead therapist on several psychedelic medicine clinical trials and currently consults for Compass Pathways as a mentor to the therapists working on their phase 3 trial of psilocybin for treatment-resistant depression. Dr. Thayer is the Lead Instructor for Numinus's psychedelic-assisted therapy certification program and co-hosts Numinus's podcast, Psychedelic Therapy Frontiers. Dr. Thayer has a private therapy and coaching practice where he helps people resolve the unconscious blocks keeping them from creating the happiness, wealth, freedom, and relationships they crave. Highlights: From military psychology to psychedelic therapy Personal explorations with ketamine and psilocybin Psychedelics for mental health and spiritual exploration Integrating psychedelics into therapy and coaching Motivation for entering the psychedelic industry Bringing psychedelic awareness to the unconscious mind The potential for harm in the psychedelic underground Principles of effective psychedelic facilitation Assessing personal readiness as a psychedelic facilitator Experiential MDMA training for therapists Balancing evidence-based and spiritual approaches Episode Sponsors: Apollo Neuro - Third Wave listeners get 15% off. Soltara Healing Center: Use code TW200 to receive $200 off your next retreat.

Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD and Lykos Therapeutics (1:35). Recent news a blessing in disguise for Cybin, COMPASS Pathways and MindMed (14:30)? Trial data and cash in the bank are top signifiers of success (22:35). How Atai fell behind and dropped out of the conversation (24:00). Upcoming catalysts - patience required (26:35). For psychedelic medicine, does it matter who's in the White House (29:30)?Read episode transcriptsShow Notes:FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks UnchangedMindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating FactorsATAI: Enormous Potential Upside But No Clarity YetDe-Risking Psychedelics: Compass Pathways, Cybin And AtaiFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

In this next episode of The Heidrick & Struggles Leadership Podcast, Heidrick & Struggles' Charlie Moore speaks to Kabir Nath, the CEO of Compass Pathways. Compass Pathways is a company dedicated to studying investigational psilocybin treatment in treatment-resistant depression, post-traumatic stress disorder, and anorexia. Kabir Nath, whose career has spanned approximately 30 years in the biopharmaceutical and medical device industry, was previously the senior managing director of the global pharmaceutical company Otsuka Pharmaceuticals. In this conversation, Nath shares what attracted him to the biotech space and what it's like to take over the helm of a company from founders, and how he's collaborated with them during the transition. He also discusses his perspective on healthcare accessibility, evolving an organizational culture as the business grows, what new skill sets or capabilities he is looking for in talent, and how he manages investor relations. Finally, he shares how he is preparing the leadership team for the organization's continued transformation over the next few years. Hosted on Acast. See acast.com/privacy for more information.

Let's celebrate. This is episode 100! My guest is Jonathan Sabbagh, Co-Founder of Journey Clinical and I talk about normalising Ketamine therapy for all, plus why PTSD can fire up your career - until you realize it is harmful to you. Since a few years I am following Jonathan and his wife and Co-Founder Myriam Barthe's great work around the idea to build a strong, decentralized network and offerings for KAP (Ketamine Assisted Psychotherapy) to empower as much therapists as possible to execute the therapy. They did an incredible and successful job to make Ketamine therapy available and build a strong system in collaboration with therapists and doctors.In this episode is talk to Jonathan about: -how PTSD can give you a skyrocketing career, until you realiize your “energy” is trauma in disguise-how we both were very good in PTSD friendly jobs (banking & media) and left them because we realised our own PTSD -how Journey Clinical helps therapists to support their patients with ketamine therapy, (eventually psilocybin) if they are interested in trying and why normal “therapy” needs a strong transformation What Journey Clinical doesJourney Clinical is on a mission to transform the growing mental health crisis by accelerating the mainstream adoption of legal, evidence-based Psychedelic-Assisted Psychotherapy as the standard of care for mental health, starting with Ketamine-Assisted Psychotherapy. They have built a leading platform for Psychedelic-Assisted Psychotherapy in the US. They also recently announce a research collaboration agreement with Compass Pathways to inform the development of a scalable delivery and training model for COMP360 psilocybin treatment. Which means, together with Compass, they work on a future delivery model for psilocybin therapy. INFO@journeyclinical @Jonathansabbaghwww.https://www.journeyclinical.com/. Hosted on Acast. See acast.com/privacy for more information.

Atai Life Sciences co-founder and CEO Florian Brand discussed initial results from Beckley Psytech's phase 1 trial of its patent-protected psilocin ELE-101 in patients with major depressive disorder. Brand explained that ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin, developed for depression treatment. The IV formulation aims to reduce treatment duration to two hours, compared to the longer sessions required by traditional psilocybin and LSD treatments. Phase one trials in healthy participants showed that ELE-101 was well tolerated with no serious safety concerns and had a predictable pharmacokinetic profile, supporting dose selection for phase two trials. Brand highlighted the commencement of phase 2 trials with the first patient already dosed. This study involves 6 to 12 patients, with data expected in the second half of this year. atai Life Sciences is optimistic about the shorter treatment duration, potentially making it more convenient for patients and less burdensome for the healthcare system. Additionally, Brand mentioned their involvement with Compass Pathways, which is developing psilocybin therapy, and noted the importance of the two-hour treatment paradigm established by the intranasal esketamine spray, Spravato. This paradigm could be leveraged for their other compounds, such as BPL-003 and DMT, also being developed for depression treatment. #AtaiLifeSciences, #Elly101, #Psilocin, #Psilocybin, #DepressionTreatment, #IVFormulation, #Pharmacokinetics, #ClinicalTrials, #MentalHealth, #Psychedelics, #PhaseTwoTrials, #HealthcareInnovation, #CompassPathways, #Spravato, #Esketamine, #ShortDurationTherapy, #BPL003, #DMT, #Neuropsychiatry, #FlorianBrand #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca. In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine.    In this episode you'll hear: The history of ketamine The pharmacology of ketamine's dissociative effect The relationship between ketamine dose and antidepressant effect  The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments   Quotes: “We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.” [10:58] “Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.” [23:19]   Links: Dr. Eriksson on LinkedIn HMNC Brain Health on LinkedIn HMNC Brain Health website Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD Psychedelic Medicine Association Porangui

Daniel Lametti and Joanna Kuc join Robb and Josh to share the advanced chatbot they created for a research project in mental health. Dan Lametti is an Associate Professor of Cognitive Psychology at Acadia University in Nova Scotia, Canada. Dan taught and conducted research in experimental psychology at the University of Oxford, and is also the Director of Academic Fellowships at OneReach.ai. Joanna is a Data Scientist at Compass Pathways as well as a PhD Candidate in Experimental Psychology at University College London, where her work focuses on decoding language biomarkers relating to mental health. Using the OneReach.ai platform, Daniel and Joanna created a conversational app in Telegram that collects journal entries from participants as either written text or voice notes, and generates weekly summaries. Learn more about this unique design process and some of their findings in an engaging and practical episode of Invisible Machines.

Sunny Strasburg, LMFT and I discuss the benefits that Ketamine and other psychedelics have provided and continue to provide people who struggle with depression, anxiety, PTSD and more. We talk about how and why this works scientifically as well as go through the entire process of what patients can expect. Sunny Strasburg, LMFT is certified in Psychedelic Assisted Psychotherapy by the California Institute of Integral Studies. She has been trained in psilocybin therapy by Compass Pathways and Synthesis. She is also a trainer for the Theradelic Approach, and hosts KAP retreats. Mrs Strasburg serves as a consultant for licensed practitioners. Follow Sunny at: sunnystrasburgtherapy.com IG: @sunnystrasburglmft Her Book: The Theradelic Approach

In a recent insightful interview, George Goldsmith, the visionary entrepreneur and founder of Compass Pathways, shared the rich tapestry of his life and career. He has had a journey that unfolded in unexpected ways, defying conventional norms.

In this episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D. once again take over hosting duties, this time interviewing Gül Dölen, MD, Ph.D.: Associate professor of Neuroscience and Neurology at the Johns Hopkins University, School of Medicine, and head of the Dölen lab. Dölen largely researches the neuroscience behind social behaviors and is most known for her work in establishing how psychedelics reopen critical periods of learning, and that the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they're open for, and which therapeutic frameworks and integration practices could best take advantage of them. Her most recent research was giving MDMA to otherwise very asocial (and violent) octopuses to prove that a drastically different species would exhibit typical MDMA-inspired prosocial behavior. And, after discovering that all the classic psychedelics worked to reopen critical periods – that psychedelics are apparently the master key to opening these periods – she's now researching why, through the PHATHOM project (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability). You will likely learn a ton in this episode: why critical periods close as we get older and what may impede them from opening more often; how plasticity and metaplasticity relate to each other and why increased neuroplasticity isn't always a good thing; how the length of different psychedelic experiences relates to efficacy; why the different results of MAPS' and Compass Pathways' studies show the importance of therapy; how autism could be related to critical periods; why repeated psychedelic use may make it harder for one's brain to reset; and how important context is in the ability to reopen critical periods – especially around social learning. Click here to head to the show notes page. 

In this episode of the Psychedelic Podcast, Paul F. Austin welcomes Christian Angermayer, a serial entrepreneur and investor in psychedelics, longevity, fintech, crypto, and future tech. Get full show notes, links, and transcript here: https://thethirdwave.co/podcast/episode-207-christian-angermayer/ Christian is a notable figure in the field of psychedelic medicine, both respected and controversial. He has been a driving force in pushing psilocybin toward FDA-approval. But his company atai Life Science's psychedelic patents have drawn criticism from decriminalization-first advocates. Some wonder if the medical approach to psychedelics conflicts with the idea of open access and shamanic usage. Christian delves into this question, examining opposing views and exploring other dichotomies, such as whether capitalism and spirituality can coexist in the realm of psychedelics. He also considers the potential conflict between the search for psychedelic wisdom and the desire for immortality. Christian's conversation with Paul presents a new perspective on psychedelics, exploring nuanced topics and questioning the future of psychedelic biotech, microdosing, and longevity science. Christian Angermayer: Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives. Christian's family office and private investment firm, Apeiron Investment Group, has more than USD 2.5 billion under management and 50 people across five international locations. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Experiences, and Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns. Christian is the world's largest investor in psychedelics and is recognized for leading the current psychedelics renaissance. He founded atai Life Sciences, investigating the potential of psychedelic compounds including psilocybin, ketamine, DMT, and ibogaine as approved medical treatments. Highlights: Exploring psychedelics and the evolution of organized religion. The parallels between ancient psychedelic traditions and modern medicalization. An argument for democratizing psychedelic access through centralization. Christian's thoughts on creating a regulated framework for microdosing. Optimism about longevity research and extended lifespans. Overcoming deeply-rooted fears and embracing the concept of a long life. Christian's challenges and successes at COMPASS Pathways & atai Life Sciences. The obstacles of commercializing psychedelic medicines in an economic downturn. Investigating how psychedelics might contribute to longevity. How psychedelics can help us find and live our Dharma (life's purpose). Key Links: Apeiron Investment Group: https://apeiron-investments.com/ atai Life Sciences: https://atai.life/ COMPASS Pathways: https://compasspathways.com/ Episode Sponsors: Apollo Neuro. Third Wave listeners get 15% off. Third Wave's Mushroom Grow Kit - use code 3WPODCAST to save $75.

Today I am speaking with Dr. Manish Agrawal.Manish is the founder and CEO of Sunstone Therapies and co-director of clinical research at Aquilino Cancer Center in Rockville, Maryland.Manish studied engineering at Auburn University and graduated from the University of Alabama School of Medicine. He did his medical residency at Georgetown University, where he also earned a master's in Philosophy. After Georgetown, he did a fellowship at the National Institutes of Health.He then went on to a more than 20-year career as an oncologist.In 2017, Manish met Roland Griffiths from Johns Hopkins University, and his interest in psychedelic research was piqued, which led to the founding of Sunstone Therapies. Sunstone serves as an independent research site that carries out clinical trials for psychedelic drug developers like MAPS, Usona, and Compass Pathways, as well as their own investigator-initiated trials. They also train therapists. In this episode, we discuss:* Manish's career as an oncologist and researcher;* His time at the National Institutes of Health (NIH);* The role his philosophy training has played in his life as a physician;* The origin story of Sunstone Therapies;* The similarities between delivering cancer treatment and the delivering psychedelic medicine; and * Preparing for FDA approval.Listen to the episode on Substack, Spotify, Google, or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTube* Theme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

Compass Pathways is leading the charge for psychedelic therapy. The research is currently in stage three trials and is expected to receive FDA approval in the next few years. An expert explains how the treatment works and if the therapy will be covered by insurance. Learn More: https://radiohealthjournal.org/is-psychedelic-therapy-the-future-of-mental-health-treatment Learn more about your ad choices. Visit podcastchoices.com/adchoices

Will tough times continue for psychedelic stocks? (1:50) Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways (4:20), Atai and Cybin (19:50) and the inevitability of big pharma buying up assets (32:10).Transcripts available on Seeking AlphaCybin: A Leading Early-Stage Psychedelics PlayAmerican Medical Association approves CPT code for psychedelic therapiesFDA drafts new guidance on psychedelic researchPsychedelic Sunday: Scrutinizing Psychedelic Stocks

Graham Pechenik, founder and patent attorney at Calyx Law, joins The Psychedelic Podcast to delve into the complex world of patents and their impact on the psychedelic landscape.  Find episode links, summary, and transcript here. Pechenik raises thought-provoking questions about the patent system's role in fostering innovation while also potentially hindering research and restricting use. He suggests that the patent system, intertwined with regulatory and healthcare structures, often determines whether groundbreaking substances like psilocybin gain FDA approval. Pechenik also explores concerns surrounding excessive psychedelic patents, comparing the unique approaches of COMPASS Pathways, MAPS, and Paul Stamets.  As the episode unfolds, Graham and Paul contemplate the delicate balance between patent protection and freedom of use in the burgeoning psychedelics industry. Graham Pechenik is a registered patent attorney and the founder of Calyx Law, a law firm specializing in cannabis and psychedelics-related intellectual property.  Graham has a BS from UC San Diego, where he chose Cognitive Neuroscience and Biochemistry majors—after his first psychedelic experiences inspired a deep curiosity about the bases for changes in consciousness—and a JD from New York University, where he initially pursued interests in bioethics and cognitive liberty.  After a decade at large law firms defending and challenging patents for Fortune 500 companies across the agricultural, chemical, pharmaceutical, biotech, and technology industries, including working on several landmark patent cases both at trial and on appeal, Graham started Calyx Law in 2016 to help cannabis and psychedelics ventures design and implement their IP strategies.  Graham is also editor-at-large of Psychedelic Alpha, where he writes about psychedelics IP, provides data for patent trackers, and maintains a psychedelics legalization and decriminalization tracker. He is the founding steward of the IP Committee of the Psychedelic Bar Association, where he is also on the Board of Directors, and is a member of Chacruna's Council for the Protection of Sacred Plants.  Graham was raised in Oakland, CA, and currently lives in San Francisco. Highlights: Examining the unique patent process for the Stamets Stack microdosing protocol. How to enforce patents on illegal substances like psilocybin. Unpacking COMPASS Pathways' psilocybin polymorph patent. The pros & cons of psychedelic patents. How psychedelic patents could hinder therapeutic expansion. Graham's motivation to enter the psychedelic patents space. Key Links: Calyx Law Graham on Twitter Psychedelic Alpha Psilocybin Patent Tracker (blog) Microdosing Psilocybin Mushrooms with the Stamets Stack (psychedelic research) New Microdosing Study Investigates “Stamets Stack” (psychedelic research) Oregon's Psychedelic Path: What Coaches and Consumers Need to Know Episode Sponsors: Numinus Sayulita Wellness

Psilocybin–the active ingredient naturally found in psychedelic magic mushrooms–is increasingly being used to help fight what is often called ‘treatment-resistant depression' among other mental illnesses. COMPASS Pathways is one bold healthcare venture on a mission to fight human suffering at scale using a combination of a one-time psilocybin treatment, ongoing therapy and digital tools. To discuss this new direction for mental healthcare, we are joined by COMPASS Pathways Co-Founder and Chairman, George Goldsmith, as well as Ed Bolton, Creative Director of Brand in frog London. George and his team at COMPASS Pathways worked with frog to communicate their story and carve a new category for investors and patients alike.Brought to you by frog, a global creative consultancy. frog is part of Capgemini Invent. (https://www.frog.co)Find episode transcripts and relevant info (https://www.frog.co/designmind/design-mind-frogcast-ep-33-a-new-direction-for-mental-healthcare)Download the new frog report 'The Regenerative Compass' (https://go.frog.co/the-regenerative-compass)Learn more about the frog + COMPASS Pathways collaboration (https://www.frog.co/work/forging-a-new-path-for-mental-health)Visit COMPASS Pathways (https://compasspathways.com)Host/Writer: Elizabeth Wood, Editorial Director, frogResearch & Story Support: Camilla Brown, Senior Copyeditor, frogAudio Production: Richard Canham, Lizard Media (https://www.lizardmedia.co.uk)

In this episode of Psychedelics Weekly, Joe calls in from Los Angeles to cover the week's news with David.  They review:  -Dr. Julie Holland's recent appearance on the The Cannabis Investing Podcast, where she discussed the concept of cannabis being a psychedelic; -Vancouver Island University in British Columbia, Canada, planning to establish a Psychedelic Research Centre, with a focus on the historical and ethical context of psychedelic substances, using a "two eyed seeing" approach that combines Western-style science with Indigenous perspectives; -A group of investors creating a Real Estate Investment Trust (REIT) to purchase real estate for the purposes of psychedelic therapy, which, if used as the collaborative model we imagine it could be, could solve a lot of problems; -Diplo completing the Los Angeles Marathon in 3 hours and 35 minutes while under a reported 4-5 drops of LSD, and the dismissive spin mainstream media added to the story;  and a Rolling Stone article focusing on (and somewhat oversimplifying) the conflicts between the medicalization and decriminalization/legalization camps (can we just do both?). The articles of course lead to much larger discussions: how cannabis has helped David overcome OCD; the need for more transparency and a review system based on abusive behavior in the psychedelic space; the idea of collectivization in therapy models; why we need to agree on ethical foundations; and our general misunderstanding of IP and IP law: was all the criticism of Compass Pathways unwarranted? www.psychedelicstoday.com  

Welcome to episode two hundred of Future Fossils! On this episode, I'm joined by Ehren Cruz (LinkedIn, Instagram, Website) and Daphne Krantz (LinkedIn, Instagram, Website) to discuss transcendence, trauma, and transformation. We talk about the festival world, our individual journeys, the rise of psychedelics in therapeutic applications, the potential of these substances, and their cultural roots. We also discuss addiction, trauma, and the consequences of collective consciousness, freedom, and how to provide access to these therapies in a way that respects Indigenous knowledge.✨ Chapters:(0:00:01) - Exploring Transcendence, Trauma, and Transformation(0:08:27) - Psychedelic Use With Intention(0:17:11) - Psychedelics and Substance Abuse(0:26:13) - Exploring Relationships to Psychoactive Substances(0:41:59) - Embodiment in Psychedelic Therapy(0:54:30) - Addiction, Trauma, and The Transhuman Conditions(1:03:20) - Healing Through Connection and Community(1:09:04) - The Freedom of Exploration(1:12:15) - Authentic Expression & Vulnerability(1:15:26) - Psychedelics for Exploration(1:27:55) - The Consequences of Collective Consciousness Freedom(1:43:02) - Supporting Independent Work✨ Support Future Fossils:Subscribe anywhere you go for podcastsSubscribe to the podcast PLUS essays, music, and news on Substack or Patreon.Buy my original paintings or commission new work.Buy my music on Bandcamp! (This episode features “Ephemeropolis” from the EP of the same name & “Olympus Mons” from the Martian Arts EP.)Or if you're into lo-fi audio, follow me and my listening recommendations on Spotify.This conversation continues with lively and respectful interaction every single day in the members-only Future Fossils Facebook Group and Discord server. Join us!✨ Tip Jars:@futurefossils on Venmo$manfredmacx on CashAppmichaelgarfield on PayPal✨ Affiliate Links:• These show notes were supplemented with Podium.Page, a very cool new AI service I'm happy to endorse. Sign up at https://hello.podium.page/?via=michael and get three free hours and 50% off your first month.• I transcribe this show with help from Podscribe.ai — which I highly recommend to other podcasters. (If you'd like to help edit transcripts for the Future Fossils book project, please email or DM me: Email | Twitter | Instagram)• BioTech Life Sciences makes anti-aging and performance enhancement formulas that work directly at the level of cellular nutrition, both for ingestion and direct topical application. I'm a firm believer in keeping NAD+ levels up and their skin solution helped me erase a year of pandemic burnout from my face.• Help regulate stress, get better sleep, recover from exercise, and/or stay alert and focused without stimulants, with the Apollo Neuro wearable. I have one and while I don't wear it all the time, when I do it's sober healthy drugs.• Musicians: let me recommend you get yourself a Jamstik Studio, the coolest MIDI guitar I've ever played. I LOVE mine. You can hear it playing all the synths on my song about Jurassic Park.✨ Mentioned & Related Episodes:7 - Shane Mauss (Psychedelic Comedy)10 - Anthony Thogmartin & David Krantz (Future Music)27 - Rak Razam & Niles Heckman (5-MeO DMT & Consciousness)58 - Shane Mauss (Psychonautic Adventures at the Edge of Genius & Madness)59 - Charles Shaw (Trauma, Addiction, and Healing)62 - David Krantz (Cannabis Nutrigenomics)68 - Charles Shaw (Soul in the Heart of Darkness)96 - Malena Grosz on Community-Led Party Culture vs. Corporate "Nightlife"100 - The Teafaerie on DMT, Transhumanism, and What To Do with All of God's Attention103 - Tricia Eastman on Facilitating Psychedelic Journeys to Recover from An Age of Epidemic Trauma112 - Mitsuaki Chi on Serving the Mushroom117 - Eric Wargo on Time Loops: Precognition, Retrocausation, and the Unconscious131 - Jessica Nielson & Link Swanson on Psychedelic Science & Too Much Novelty136 - Alyssa Gursky on Psychedelic Art Therapy & The Future of Communication156 - Stuart Davis on Zen, Aliens, and Psychedelics168 - Mikey Lion & Malena Grosz on Festival Time, Life-Changing Trips, and Community in COVID171 - Eric Wargo on Precognitive Dreamwork and The Philosophy of Time Travel172 - Tyson Yunkaporta on Indigenous Systems Thinking, Fractal Governance, Ontopunk, and Queering W.E.I.R.D. Modernity176 - Exploring Ecodelia with Richard Doyle, Sophie Strand, and Sam Gandy at the Psilocybin Summit✨ Keywords:Transcendence, Trauma, Transformation, Festival World, Psychedelics, Therapeutic Applications, Cultural Roots, Addiction, Collective Consciousness, Freedom, Access, Indigenous Knowledge, Intentionality, Context, Consumer Culture, Spiritual Ego, Health Coaching, Mental Health Counseling, Gender Identity, Substance Abuse, Private Practice, Ancient Cultural Roots, Modern Therapeutic Applications, Transformational Festival Culture, Memory, Embodiment, Rat Park Experiment, Brain Inference, Harlan Ellison, Opioid Crisis, Connection, Community, Oppression, Systems of Power, Self-Harm, Interconnectedness, Consumerism, Mindset, Serotonin, Oxytocin, Courageous Expression, Authentic Self, Right Wing Psychedelia, Commodification, Marginalized Groups, Nurturing Attachment, Reality, Independent Work, Apple Podcasts, Patreon✨ UNEDITED machine-generated transcript:Michael (1s):Greetings, future fossils. This is Michael Garfield welcoming you to episode 200 of the podcast that explores our place in time. My God, we made it here. What a view from this summit. It's incredible. And for this episode, I have two very special guests, two very old friends. I mean they're, they're not very old, they're just friends I've had for a very long time. Aaron Cruz and Daphne Krantz. Aaron is a psychedelic experience facilitator. Daphne is an addiction counselor, but I met them both in the festival world when Aaron and I were working on the Visionary Art Web Magazine Sole Purpose back in like a decade ago.Michael (55s):And Daphne was producing electronic music under the Alias FU Texture. Dabney was a self-identified man at the time. David Krantz appeared on the show, episode 63 talking about cannabis and Nutrigenomics. So I mean, all of us have been through just extraordinary transformations. Aaron Cruz was the guy whose ceremonially blessed my Google Glass before I performed with it in a world first self streaming performance Gratify Festival in 2013.Michael (1m 35s):So yeah, there's a lot of archival material to unpack here, but we don't spend a lot of time ruminating on history. Instead, we discuss the present moment of the landscape of our society and people's trauma and drive for transcendence and the way that this collides with consumer culture and transformational festival scene where we all met one another. And it's an extraordinary episode and I know a lot of people out there are having a really hard time right now.Michael (2m 23s):And I am with you. I have huge news to share soon. I want you to know that you are not alone in your efforts to work things out. And if you need support, there is support for you. I really hope that you get something out of this conversation. I myself found just simply re-listening to the recording to be truly healing. And I'm really grateful that I get to share it with you. But before I do that, I want to pay tribute to everyone who is supporting this show on Patreon and on CK everyone who is subscribing to my music on Band camp, the latest Patreon supporters include Darius Strel and Samantha Lotz.Michael (3m 17s):Thank you both so much. Thank you also to the, the hundreds of other people who are helping me pay my mortgage and feed my kids with this subscription service one form or another. I have plenty of awesome new things for you, including speaking of psychedelics, a live taping of the two sets I just played opening for comedian Shane Moss here in Santa Fe. John Cocteau Cinema sold out shows. Excellent evening. I just posted the little teaser clip of the song Transparent, which was the song from that 2013 Google Blast performance.Michael (4m 2s):Actually that was, its its inaugural debut and I've refined it over the last decade and I submitted it to NPRs Tiny Desk concert. And you can find that up on my YouTube. If you want to taste of the electro-acoustic inventions that I will be treating subscribers to here in short order patreon.com/michael garfield, michael garfield.ck.com, which is where this podcast is currently hosted RSS feed. And thanks to everybody who's been reading and reviewing the show on Apple Podcast and Spotify and wherever you're wonderful, you've got this, whatever you're going through, you can do it.Michael (4m 46s):I believe in you and do not hesitate to reach out to me or to my fabulous guests or to other members of our community if you need the support. Thank you. Enjoy this episode. Be well and much more coming soon. I have two extraordinary conversations in the Can one with Kevin wo, my dear friend here in Santa Fe and Kmo, the notorious, legendary confederate podcaster who just published a trial log, the first part of the trial log between the three of us on his own show.Michael (5m 27s):Highly recommend you go check that out. And then also an episode with Caveat Magister, the resident philosopher of Burning Man who published an extraordinary book last year, turned your Life into Art, which resulted in a very long, vulnerable, profound and hilarious conversation between the two of us about our own adventures and misadventures and the relationship between Psycho Magic and Burning Man and Meow Wolf and Disney and Jurassic Park. Oh, and speaking of which, another piece of bait to throw on the hook for you subscribers.Michael (6m 12s):I am about to start a Jurassic Park book club this spring. I will be leading the group in the Discord server and in the Facebook group and on live calls chapter by chapter through the book that changed the world. I've an intense and intimate relationship with this book. I was there at the world premier in 1993. I grew up doing Dinosaur Diggs with the book's Primary Paleontological consultant, Robert Bocker. I have a dress for tattoo, et cetera. I've sold the painting to Ian, not to Ian Malcolm, the Jeff Goldblum, but I did name my son after that mathematician.Michael (6m 59s):Anyway, yes, much, much, much to discuss, especially because you know, one of the craziest things about this year is that the proverbial velociraptors have escaped the island, you know, and open ai. What, what's in a name? You know, everything is just transforming so fast now. And so I am the dispossessed Cassandra that will lead you through some kibbitz in Doug rush cuffs language. Please join us, everybody subscribing Tock or anybody on Patreon at five bucks or more will be privy to those live calls and I really hope to see you in there.Michael (7m 47s):And with all of that shilling behind me now, please give it up for the marvelous Aaron Cruz and Daphne Krantz. Two people with whom I can confidently entrust your minds. Enjoy. Okay, let's just dive in. Sure. Aaron Daphne. Hi, future fossils. You're here.Michael (8m 26s):Awesome. This took us like what, nine months to schedule this.Daphne (8m 30s):A slow burn, but we, here we go. It's great to hear me here,Ehren (8m 33s):Brother. It is, yeah. And once again, anything that gets rescheduled always ends up turning out better. Like I, I was just thinking, I'm really glad we actually didn't do this interview nine months ago, just in terms of life experience between now and then. I don't know what that's gonna translate to in a conversation, but personally I feel a lot more prepared to talk to you rightDaphne (8m 51s):Now. A hundred percent agree.Michael (8m 53s):Cool. Okay, so let's just dive in then. Both of you are doing really interesting work in the explosive emerging sector of, in one way or another, dealing with people's trauma, dealing with people's various like life crisis issues. And having met both of you through the festival world, which was a scene of pretty rampant abuse and escapism. And I met you both as what my friend in town here, Mitch Minno would call like psychedelic conservatives, where I felt like there were a bunch of like elder millennials who were kind of trying to help that had been in the scene for a little long and they were really working to steer people into a more grounded and integrated approach to extasis in the festival world.Michael (9m 52s):And all of us have seen our fair share of, and perhaps also lived through our fair share of right and wrong relationship to the tools and technologies of transcendence. So that's kinda where I wanna take this. And I think maybe the way to start is just by having both of you introduce yourselves and talk a little bit about your path and the various roles that you've kept over the years in this, in adjacent spheres and what led you into the work that you're doing now. And then, yeah, from there we can take it wherever the conversation chooses to lead us. Daphne, we've had you on the show before, so why don't we have Aaron go first? Let's do that.Michael (10m 32s):Okay,Daphne (10m 32s):Awesome. Thank you Mike. Yo, we appreciate you're really eloquent way of creating an environment to kind of settle into here. So Aaron Cruz, I've been really deeply immersed in psychedelics for 15 years. My first foray into the world, or in curiosity, was actually going to school in Ohio State University for fellowship in anthropology. And coming it from the perspective of looking at 16th, 15th century around the time of the, the conquest in indigenous cultures utilizing plant medicine ceremony ritual as a community harmonizer agent, as a tool for collective wisdom, also for ceremonial divine communion, but very much from an ivory tower perspective.Daphne (11m 15s):I was not very much engaged with psychedelics at that particular lens outside of a foray into a couple of opportunities at all. Good music festival or different things like that. But I beg the question about is using these plant medicines with intentionality, will it create a more symbiotic way of life? A way of understanding the interdependence between the natural landscape, humanity, culture, community building and personal evolution. So it wasn't until major psychedelic experience in 2008 where I had probably inadvisable amount of L s D in the middle of a, an event and went into a full system to dissolve to the, the good degree. I actually didn't even know my name for several hours, but, but what I did feel that came to recognize was just this deep sense of connection to the soul of, of others.Daphne (12m 4s):A sense that e, each one of us sped our best efforts with cultural conditioning, social conditioning, how we're races, peers, we had a desire to appreciated, embraced. There's this deep sense of tribal kinship that I think I felt from everybody wanted to explore whether they were wearing a grateful dead shirt, a ballerina tutu or flat cap or whatever it was. And we wear these different types of masks of her own safety and security and and sense of self. But beneath that facade, I just felt this deep, rich desire to be a sense of belonging and connection and desire to be a p a child of the universe for lack of a better term. So that kind of really set me off from that tone as you shared, is that this rapidly accelerated from place of recreation to a deep of place of deep spiritual potency.Daphne (12m 46s):And, and from that place on the alchemical frontier, as I call that kind of festival type of realm where many, whether they're using compounds for escapism or they're trying to embody or embrace a particular lifestyle that they can then translate and seed into their own default realities or wherever that is almost train Jedi training grounds or whatever you could consider that to be. However, your orientation around it, that is, I just felt a deep devotion to trying to support those particular realms. First through workshop ceremony and cultivation of experiences that had some integrity and bones to using these things mindfully, actually to producing events. I was producing a co-producing original back in the day where I believe I met you, Mike, with root wire with the popio about 2010 through 2013 or nine through 12, maybe one of those epox learned a lot.Daphne (13m 35s):It was a lot of bootstrapping and blood, sweat and everything else trying to get the, those events going and, but they're really creating these containers for radical creativity and self-expression and where music and visionary arts could be upheld in a new model of, of honoring them and mutual out something that never took, took root as much as I would love it to. And then kind of translated into producing Lee Festival out here in Asheville, North Carolina for six years. And the ethos behind that was trying to create a dynamic cultural atmosphere, 10 to 15 different nations, people of all walks of life and traditions expressing their music arts culture ceremony and using that as a catalyst to kind of break down isms to reveal that the true depth and value that the rich, creative and cultural expression has beyond politic, beyond social conditioning.Daphne (14m 21s):It's a, you hear one thing about Iranians on on tv, but if you see them doing their Sufi circle dance and chanting and when they're cooking their food at the end of the day, it just really, it's amazing how humanity and expression in those places would really quickly help people bypass certain prejudices without saying a word. We're often dialogue, even intentional and conscious dialogue tend to fail. The expression goes beyond that. So, and of course there is still a rich culture of psychedelics and but these places are, it's kind of underground. It's not necessarily, there's no curated container specifically to facilitate initiation of rights of passage. It's a little bit more rogue, rogue experiencing.Daphne (15m 2s):So after that kind of materialized up to Covid where I was really actually even at that point seeking an exit strategy from that realm, the intensity of producing events is extremely vigorous. I remember in 2019 I had 7,800 emails and countless calls just coordinating three festivals and I'd have children, my three girls just hanging on every limb. And that one more call, one more, one more thing. So it was becoming quite burned out and Covid kind of did me at the time. I didn't think so a bit of a favor and giving me, kind of forcing me into an exit strategy to re-identify myself, not as just a producer and an event organizer, but someone that is deeply passionate about initiatory culture. My catalyst was festivals for initiation or creative initiation.Daphne (15m 43s):And then I went back to where it all began, really sat with the medicine once again, brought myself back into sacramental ceremony. And then I started really gazing at the broad sweeping frontier, the vanguard of the psychedelic emergence now, and saying, this may be a time I could be transparent and real and open about my deep care and use of these plants and medicines for almost 15 years. And so I went ahead and I got a professional coaching certification from I C F, I got a third wave psychedelic certification. It was the first a psychedelic coaching program in the nation back in 2020, in six months of learning the panoramic of psychedelics, preparation, integration, the neuroplasticity, the ethics considerations, dosaging compound understanding.Daphne (16m 24s):So getting that whole holistic review and then the cultivating a practice, a facilitation coaching practice based upon using that psychedelic as a catalyst but in a continuum of deeply intentional self-work and self-care and, and moving into that space with an openness to receive insights. But then really about embodiment. What do you do after you have those lightning bolts of revelation and how do you make that have an impact in your life? So that's been my last few years is serving as a, a ceremonial facilitator and coach in at the psychedelic realm and also a harm reductionist. People are looking for a high integrity experience but have a compound, don't really know how to go about it in a way that's intentional and safe. Really kind of stepping into that space and holding that container for them and being an ally.Ehren (17m 6s):Awesome. Daphne. Hi. Lovely to be back here with you Michael. So I'll start from the beginning and kind of give my whole story inspired by Aaron and the way he just articulated that trajectory. And I started out like we met each other. I think we might have met each other also at Root Wire back in that era. And I found myself in this world as a music producer. I was really heavily investing time and energy into building a music career, DJing, producing under the name few Texture for a long time, starting in around 2009. And that was my main gig for about six years and had some early psychedelic experiences when I was pretty young.Ehren (17m 52s):14, 15, 16 kind of set me off on a path to where I really had a strong inclination that there was something there and was always very interested in them and came into the festival world, into the music world with a very idealistic lens of what these substances could do for us individually as humanity and had my ideal ideals broken completely in a lot of ways. And what I experienced personally through relationships with collaborators, through my own inability to show up in the way that I wanted to in terms of my own ideals, thinking that because I took psychedelics, I was gonna somehow magically be this person who could live up to these ideals of relational integrity and honesty and like really being a beacon of what I perceived as like light, right?Ehren (18m 50s):And really had some issues with spiritual ego when I was younger and kind of had the sense of I've seen these other realms, I, I know more than other people, I'm special. I had all that story and really ended up harming me and other people around me. And it took some pretty significant relational abuse actually that I was experiencing and participating in through a creative relationship to kind of break me outta that illusion, right? That because I am creating interesting forward thinking music with a psychedelic bent in this kind of wild and free community festival community, that somehow I was immune from all of the shadow that exists in our culture in the psyche, in all of these places that I was just very blind to.Ehren (19m 44s):And I think it's a pretty normal developmental thing in your early twenties, and I mean at any age ongoing of course to be, to have places that are less conscious and those are blind spots, right? And so I really was forced through my musical career, through my participation in psychedelic culture to either have the choice to look at those blind spots or continue to ignore them. And I'd look back and I'm really grateful that I, I really did at a certain point be like, damn, I need to go to therapy. You can't do this on my own. I'm really hurting. And in about 2015 I kind of stepped away from music pretty hardcore and really shifted my focus because I was in too much pain.Ehren (20m 28s):I had experienced a lot of relational trauma around that time and started to just do other things peripherally related to music. I worked for MOG for a little bit building synthesizers and found myself doing a lot of personal healing work, kind of getting really real about my own inability to show up as what at the time I was perceiving as like a good person. In retrospect there it was so much more complex than that. And over time, being able to drop the layers of shame and the layers of self-judgment around a lot of those relational patterns I was living out that of course are familial and cultural and all these other things. But I ended up starting doing health coaching work around that time.Ehren (21m 11s):And Michael, that's something that we've connected on on the past episodes around some of the epigenetic coaching work. I do a lot of genetic testing, I do a lot of personalized nutrition, peak performance type work and was doing that pretty steadily from about 2015 to 2019 and I'm still doing it, but over the last three and a half years or so, went and got a master's in mental health counseling, started to really find that a lot of the people I was working with and drawing from my own experiences in therapy and healing, I was like, okay, nutrition and all of these physiological things are very important.Ehren (21m 53s):And what I'm seeing is most of these people need emotional healing. Most of these people need more psycho emotional awareness and healing from trauma and relational patterns. And I just felt really unprepared to do that work as a coach at the time. And also had just tremendous openings into understanding myself better into being able to, yeah, be with discomfort and be with pain in a way that when I was younger was totally off the table. It was like I'm just gonna distract myself fully from all of that through, through jugs, through sensory experiences through the festival world.Ehren (22m 37s):And that's where I got drawn and no regret, like I love that it was what shaped me and I still engage in all of that just with this slightly different way of being with it, not as an escape, but as a way of celebration in contrast with really being able to also be with the more difficult, darker shadow aspects of life and seeing that as a pathway to wholeness rather than avoiding those things. And so that's the work I'm doing now as a therapist, as someone who does psychedelic integration work. I've also done publications on psychedelics.Ehren (23m 18s):I have an article that was in the Journal of Mental Health Counseling a couple years ago. I have another one that's pending right now on psilocybin assisted group therapy that I hope gets through in the international journal group psychotherapy right now. And I'm planning some research also on gender and psychedelics in terms of the way psychedelic experiences impact gender nonconforming and gender expansive people's perception of gender. And I know for me that was one of the early indications that I was transgender was a mushroom experience when I was in my early twenties when I was like, wait, I think I'm a lesbian, I have no idea what this means. And I had no idea how to process it.Ehren (23m 58s):And I kind of stuffed it back down for years and two years until it was just too obvious. But I have, yeah, that's in the works working on IRB approval for that this year. So yeah, kind of have a research bent, do general therapy work with people, do psychedelic assisted work, also still do genetic testing, epigenetic coaching, working on more of the physiological side with people and coming from a holistic health perspective. But yeah, just also to add the other piece in here, I did my internship and worked for a little over a year substance abuse rehab as well, doing therapy there. And so as someone who's been a long time proponent of psychedelics and the potential healing capacity of them, still fully believe that despite my own, and I've had many important experiences to counter what I was saying earlier around them also creating sometimes an idealized version of self without doing the work to get there.Ehren (24m 57s):I worked in a rehab working with people who've had maladaptive relationships with substances and it was a very important counter to my own, again, idealized image and idealized perception of the human relationship with substances. And so I, coming out of that, I actually left in December starting in opening up my private practice with I think a much more balanced understanding of all the different ways humans can be in relationship to substances from full on avoidance to transcendence and self-awareness. And I really love to be able to hold both of those perspectives and work with people on all sides of that spectrum because there's not just necessarily a clean one thing one way or the other for people.Ehren (25m 45s):I find myself and Michael, you and I have talked about this weaving in and out of those relationships of where we end up relating to different substances in good or more harmful ways. And I think there's an importance to be able to be honest with ourselves and with people that we're working with around, yeah, what is this really? What is this really doing for me? And what am I getting out of this? And sometimes it's okay to lean on a substance for pain relief or for disassociation intentionally, right? But like at a certain point, like how do we learn how to take what, and I think this is true regardless of how we're using any substance, how do we learn from it and take what this substance is helping us with and kind of learn how to do it on our own in certain ways.Ehren (26m 36s):And so that's, I think maybe where this roundabout description of my life right now is leading to is that point of I'm very interested in regardless of the substance, regardless of what it is, whether it's heroin, whether you're using heroin to avoid painful emotion, how do you learn how to be without yourself, without the substance, right? Or whether you're using ayahuasca or L s D to access the transcendent and become more aware of the deep capacity for inner love and compassion that's already inside of you. Like how do you learn how to do that in a stable, grounded way on your own right? And I, I think there's a, a parallel, right that I think is lost in the discourse about drugs in general that I'd love to bring in.Michael (27m 22s):So that's actually right where I want to be for this cuz I think should not come as a surprise to anyone that there is this rather obvious isomorphism, I guess in people's relationship to ecstatic events generally to the festival as some, as a phenomenon that has its origins in the acknowledgement and re you know, the recognition and enactment of a relationship to sort of vertical access or a horizontal, like a transcendent experience of time rather than just a one damn thing after another duration Kronos clock time that there's, it's an observance of a kind of a holy dimension to our lives.Michael (28m 17s):And at one point these were all woven together much more intimately than they are today in our lives. The, the holiday has become something that is, and the festivals generally have become something that is more about a pressure valve or kind of escape from the oppression of our lives rather than something that's woven into the fabric of, or our everyday expect the observances of sacred hours in a monastic sense. And so likewise, I think if you were to believe the anthropological take on substance use, the various substances were held more like, more formally, like I think that all of us have participated in a number of discussions, are well aware of ayahuasca in particular being something that is still very much implicated within this fabric of specific cultural utility under understand and practice.Michael (29m 24s):But a lot of these things exist. For instance, ketamine is something that is either in, it's used as a medical anesthetic primarily until just a few years ago, or it's used as a club drug. And so there's a, it doesn't have that same sort of unity of purpose and the same clarity as far as the way that it's being applied and it lacks a, a lineage or a continuity where it's not like John Lilly had a, a tribe of people that he coached on how to do this. He was like people experimenting on their own. And I mean the same goes also for other, more, more recently discovered synthetic substances like L S D and also for substances that had a more focused and time-honored indigenous tradition around them like psilocybin, but either through just the proliferation of GarageBand type experimentation taking over as the primary cultural mode or whatever like we have.Michael (30m 30s):So there's this whole spectrum of the ways that different substances either have managed to maintain or never or have gotten away from, or never actually even had a system of protocols within which their use could be more or less responsibly engaged. And of course, I'm not saying that there's a ton of examples in which ayahuasca is not even within, even within settings that claim to be responsible. And anyway, this is just a nimbus of considerations around the question, which is where is the line between escapism healthier approaches or like sometimes escapism, like you just said, Daphne is actually healthy if it's encountered in a way or if we people are en engaging this in a way that is not just con ongoing peak ex seeking of peak experiences.Michael (31m 28s):I mean, I think one more thing I'll say to this is that I've seen people, and it should, I'm sure anyone listening to this has also seen people who engage traditions that are about in more, you might think like endogenous substances like running or meditation that have strong cultural containers, but there are always leaks in these containers or these containers themselves are not typically are, are not healthy. Like I've seen ayahuasca ceremonies that were the, the, that particular community depended on the patronage in order to do its work of people who had managed to kind of trick themselves into thinking that they were doing important spiritual work, but were just kind of had become gluttons or for punishment or like masochists that were just in there to purge, heal DNA traumas or whatever for their retroactive lineal healing week after week after week.Michael (32m 31s):And nothing was actually changing. They had gotten themselves into a loop. And so I'm, yeah, I'm curious how does one ever, how does one actually even begin to recognize when something has crossed over from healthy into unhealthy? Like what is, where is the line? It seems rather contextual and I mean there were, it's funny because, I mean just to bring it back to festivals and then I'll stop, it wasn't ever really clear to me. I mean, it was clear when lip service was being paid to transformation and that was a load of shit because I think that was used as a lure by and still is by event organizers and promoters to bait people into buying a ticket but wasn't really held in the right way in those events.Michael (33m 19s):And then there are times when every effort is made to do this stuff sincerely, but is not really handled in a way that makes it success, you know. And the same can be said for anything, I mean for like educational television is an example of something that people have been fighting over for almost a century. Whether the medium, whether the format of this makes these tools effective, potentially effective, problematic in their actual implementation, et cetera. So this is a much bigger conversation than a conversation about drugs really. It's a conversation about how mu how far we can engage in a particular type of relation to a, a practice of self transformation or transcendence or illumination or education or whatever before it becomes more trouble than it's worth or before.Michael (34m 11s):We need to call in some sort of balancing factor. And I'm curious to hear your thoughts at length and I'd love to hear you kind of back and forth about this.Daphne (34m 19s):Yeah, there's so much there man. That is a panoramic for sure. One of the things to kind of look at here is that the idea of the recreational use of, of a psychoactive or a psychedelic compound is 50, 60 years old. The lineage of using Sacramento entheogenic compounds is at least 40,000 years old for the time of megalithic cave paintings, size of football fields made with depth pigmentation that is with techniques that have somehow have the endurance to be still on those walls this year later is with sac ceremonial initiations and MAs and sabertooth and many mushrooms along the bottom.Daphne (34m 59s):So perhaps even people have said such as stems and McKenna, the origin of cultural or creativity of artistic creativity might have been spawned or germinated through the use of psychedelic compounds, the self-awareness and the potential for di interdimensional realization. But you look at Theon that was used with eloc mysteries, the type of reverence people have taken for one time in their entire life to, to walk to the Elian temple from Athens, the distance of a marathon fasting, moving into that experience with great care, great reverence, having an initiation with an ergo wine, a compound that's now been synthesizing the LSDs in 47. But originally was the, the rye, the barley grain, the ergot there infused into a beverage and seeing the immortality of the soul dramatized in front of you by our initiatory rights of passage theater in Egypt.Daphne (35m 50s):And you know, the temples of Ocirus, which had little mandrakes wrapped around its feet, or isis, which had little mushrooms at the feed. And those particular lineages of priesthoods and priestesses would utilize compounds to commune and learn the subtle language of that particular medicine in collaboration with ritual and practice to help to uphold virtues of different aspects of the civilization. And you go all around from the flesh of the god's, Aztec, MasTec, olmec, TOK cultures, ayahuasca, there's probably 10 different brews in that region, thousands of years old Abor, pati bush, west Africa, psilocybins everywhere, Druids Nordic culture.Daphne (36m 31s):I mean, but you look at the way upon which peyote cactus, you used it in a way that was like, here is an ally, here is a teacher, here is a compatriot a an essence of something that I work in cohesion with in order for me to learn how to navigate my own life evolutionary process in greater symbiotic relationship with the world around me, how I commune with the divine and with more, I guess visceral potency to allow that philosophical faith that aspiring Christians across the world hold this philosophical arm length faith that when things go sour where send in love and light when things are fine, I forget I'm even affiliated or associated with any kind of denomination.Daphne (37m 15s):And it's really an interesting thing when you have a different mindset of we are in a continuum of connectivity to an interdimensional web of life and that there's an interdependence between us and these different realms of being to try to embody and embrace a life that is a virtue or an integrity or create community based around these deeper ethics and values that are being kind of almost divinely inspired. And now you're coming into a timer where that has been systematically eradicated beyond all else, whether it's the early Catholic church with the Council of naia, that plant medicine, the original Nixon move was in 3 89 ad pretty much when plant medicine was absolutely persecuted feminine that he, the hosts or the feminine energy that often was the catalyst of working together in communion with the plants and offering it the original catacombs, the nasta catacombs where they find ergot wines and such that probably the original Eucharist was a psychedelic medicine.Daphne (38m 13s):All of that was completely ousted and nothing has been persecuted harder than plant medicine. And so then coming into contemporary society, the reintroduction, whether was through the scientific land, rogue experimentation, GaN coming up with massive amounts of compounds, Albert Hoffman. But when it started to infuse into academia, it again started moving people into this awareness that is, this compound is not just therapeutic, it is creating something within it that is inspiring Nas, a deeper wisdom, a deeper sense of internal communion with life force that is beyond something that can be charted on a bar graph or triangulated with an abacus.Daphne (38m 56s):And so that, and then they, the considerations of set and setting and if you're gonna host an experiment, how do you, how do you hold a psychedelic space without being on a psychedelic? And there is a lot of challenges there because it just, it is a type of experience that almost necessitates an A, a visceral embodied awareness to even understand how to support in any kind of way because of the potency and the gravity and the expansion of what that is is something you can't read on chapter seven and have a good grasp on how to facilitate or how to curate. But that whole experience, what it ended up happening is that the disruptive nature of people thinking, perceiving, expanding in a way that is unformed or nonconform to the status quos growing industrial complex and commercial material culture created a real schism reality.Daphne (39m 47s):And so people that felt like they wanted to embrace and imbibe had to flee, had to go to the woods and had to lock themselves. And Stella Stellar or like Chris Beige who just came out with L S D in the mining universe of absolutely prolific book for 20 years, had to hide his L S D ceremonial work and testing and deep psychospiritual results until he was 10 years past 10 retired to, to finally come out with the fruits of his labor. It just created his isolatory world and framework. And so now we're saying, escapees, please come back. Like you all had to run away to do your compound and try to find yourself and your consciousness, but you, we want you back in community and the old deadheads and those that are kind of in that lineage is like, it's just not safe over there.Daphne (40m 30s):We're gonna keep it in the parks, we're gonna keep it in the fields and if we come back over there, we're gonna be always outcasted as the hippies that are just avantgarde and fringe. And so it's a real interesting dynamic in culture where we want to infuse the intelligence and the beauty of the transformation that these things can uphold. But then we don't actually have a paradigm that allows people to be expansive and allows people to be avantgarde and ecstatic in these different things without feeling that they're actually a real challenge to our core sets of cultural beliefs. So part of this kind of third wave that we're seeing right now is the reintroduction of that outcasted, psychedelic culture.Daphne (41m 10s):And it's now in a, into a space of deeper therapeutic respect where they're seeing through the results of John Hopkins in Imperial College of London and all these other studies that the power in P T S D complex, P T S D and a addiction and trauma for, with intentionality with a progressive path that includes a holistic wellbeing, body, mind, spirit care, deep intentionality, using it as a catalyst, catalyst and integration process that this can be something that can allow somebody to at least get a sense where is that inner compass, where is that inner sense of who I am? And it's an immersive culture, so you kind of drip dry, you dunk 'em in that space, they get, oh, that's what home is. I, okay, I remember, oh wait, it's going away from me.Daphne (41m 51s):It's go, I'm starting to forget. And that's where devotional practice and self-care and all those things are the real way to really supporting and sustaining that. But I think where psychedelics help is it imprints or imbues a remembrance of where that space is and to your port Michael, like once you get that deep message, then it's time to do the work. What decisions in my life, what relationships, habits, patterns, distractions, what is in my life that is taking me away from that center, make those earnest actions, make those earnest choices, and then have a sense of where that foundation is. Then if you name for growing, maybe you do revisit with the medicine in an alliance in a way that is understanding that it isn't, it's an aid, it's not a, it's not a panacea, it's never meant to be, but it helps you at times to say, okay, here's a reminder, here's your truth, here's where you can be if you let go of the drama, the guilt, shame and baggage and, but really you still got a lot of work to do on those faces before you can say that you're, we're all we're a whole.Daphne (42m 48s):So there's a nice, there's a nice kind of panoramic or a dance going on here with this third waves trying to rebrace indigenous culture and the long lineage of ceremony, trying to respect the research, trying to bring people back from the fridge of alchemy and then trying to bring about awareness to those that have been tabooed for 50 years in the Nixon war. That there's actually some vitality and merit to re reengaging with this consciousness expansion. Beautiful.Ehren (43m 12s):I wanna pick up on a couple pieces there, Erin, especially around the embodiment piece and where I see that as being a really critical component of the way that psychedelics are being reintroduced into the therapeutic community, into the way we're looking at this. And I kind of want to frame it in the context of the way Western psychotherapy has developed over the last 100 years because Michael, as you brought up, we don't have a lineage necessarily that we're drawing from. As these things are starting to become back, back into research, back into culture. John Lilly didn't have a tribe to draw from, right? He didn't. He was out there outlaw on his own doing it.Ehren (43m 55s):And in so many ways, what we're seeing right now is the people that have been experimenting, coming back together, having the capacity to get federal grant fund private funding and having these inroads into saying, all right, now that we've had these experiences, how do we codify them and provi present them in a way that's palatable to the skeptics, to the people that have assumed that this is just for hippies and people that you know off their rocker, right? And what I wanna look at is like the sense of when psychedelics were being explored in the fifties and sixties, the dominant modalities and theories that were being used therapeutically were still very Freudian and psychodynamic, psychoanalytic really meaning that predominantly they were mental, there was not necessarily the component of the body being brought in gestalt therapy, definitely the early kind of version of a lot of somatic therapies that are more popular now.Ehren (44m 57s):But that wasn't popular therapy at that time. It was being developed in the fifties and sixties, but it didn't make its way into a larger mainstream understanding of the importance of an embodied relationship to the mind and to the emotions until much later on, and especially in the nineties, early two thousands and up to now, there's been a pretty strong somatic revolution in psychotherapy saying, we need to incorporate the body, we need to incorporate the way that most people have heard at this point, the idea that trauma is stored in the body, in the nervous system. And there's absolutely a truth to that and it's kind of an oversimplification of it, but it's true that order to access the, the way we can reprocess memories, the way we can re-pattern our nervous systems, like we do have to include the body for the most part.Ehren (45m 49s):Sometimes inside is enough, but rarely, right? And so that's the trap that psychotherapy and talk therapy found itself in for a long time was not including that. And so that was also the frame that psychedelic work was being looked at when it was being researched in the fifties when it was being explored also through the kind of the outliers as well. I don't think there was as much of a com a understanding of that embodied nature of the experience as we're talking about now. And when you look at some of the models that are being put forth, I'm specifically thinking of Rosalyn Watts at Imperial College in London has this really beautiful model called the ACE model or accept connect and body model that they're using in psilocybin research that really includes the body, right?Ehren (46m 40s):Includes the what is happening in your body in this moment as you're experiencing this, and is it possible to move towards this and treat whatever is happening, whether it's painful, disturbing, difficult to be with compassion and with acceptance. And that parallels most, if not all of the current understandings of some of the best ways to do therapy with people looking at things like internal family systems or EMDR or many of the therapeutic modalities that essentially ask people to revisit traumatic memories or traumatic experiences, traumatic emotions with a deeper sense of love and compassion.Ehren (47m 20s):And when you look at the core of a lot of what the psychedelic research is showing, I think around why these things work for trauma healing, why these, these things work for PTs D, why these things work for longstanding depression or addiction, it's because they do give people access, like you said, Aaron, to that remembrance, right? To that remembrance of I'm more than this limited ego self that experiences pain and suffering. I actually have access, I can remember this access to some source of love that I feel in my body, I feel in my heart. And I can use that as a way to soften and be with the parts of me that I generally don't want to be with.Ehren (48m 2s):Like it opens up that capacity to do that. And it's the same thing that I do with clients through internal family systems and other ways of psychotherapy. It just magnifies that capacity for people to find that within themselves really fast and really quickly. You know what I mean? If you've ever done M D M A, like you just wanna love everyone, you feel it. It's an embodied experience, right? And so the levels of that which people can access that in those states gives people this greater capacity than like you said, to almost bookmark that or have a way of coming back to it, remembering ongoing.Ehren (48m 43s):And so that's the integration work. And I wanna bring this back, Michael, also to what you were saying about the institutions of festival culture, taking these experiences and marketing them as transformational and actually somehow pulling that label away from that embodied experience of what it's like to have that remembrance that into the right conditions and circumstances creates the conditions for internal transformation through that remembering, right? Like that's the individual experience that sometimes happens in a place where you have autonomy to do whatever drugs you want and beyond whatever wavelength you want to get on with a bunch of people who are also doing the same thing, right?Ehren (49m 32s):That approximates in some ways what we're seeing in the therapeutic research, just not in a contained setting, right? And then seeing festival culture kind of take that and label the festival as that rather than the experience that some people have as that. And I think that it brings up this larger conversation right now around the psychedelic industry and what we can learn maybe from the failures of transformational festival culture and the successes when we're talking about how psychedelics might be marketed to people as a therapeutic tool. Because I see the exact same pitfalls, I see the exact same appeal to any company that wants to present the psychedelic experience as inherently healing no matter what.Ehren (50m 22s):In the same way that a transformational festival wants to present the idea that coming to this festival is gonna gonna create transformation for you no matter what, and leaves out all of the specific conditions and containers and importance of all the pieces that come together to create the safety, create the container, create the, the ripening of that internal remembering and what do you do with it, right? What do you actually do with it? What, how are you being prompted to know what to do with it? And I too, Michael, remember the notion of the transformational festival and going, what does this actually mean?Ehren (51m 2s):What are we trying to transform into? What is this? What is this thing? What is this buzzword? And it's funny because the most of the transformation I, I've experienced in my own life has come from outside of that. And then those experiences now actually are like these celebratory experiences that I'm not running away from at the time they were more these escapist type things. And again, I'm gonna steer it back to that question of like, where's that line? Because I, I think it's in context with all this, all the things I was, I've just mentioned around, it's so contextual, it's so individual around where that line is for people. It's so individual where that line is between going and wanting to have an experience versus actually having it.Ehren (51m 50s):And there's no way for me or you or Erin to be an arbiter of that for someone it has someone deciding, but doing it in an honest way, right? Of like, how much am I actually moving towards parts of myself that I haven't been able to be with or haven't been able to understand or haven't been able to find love and compassion for or treat in a way that's more humane or more in relationship to a higher set of ideals or perhaps a more maybe something like an indigenously informed I set of ideals around interconnectedness and how much am I continuing to engage with substances as a way to trick myself into thinking that I might be doing that or that just I'm straight up just having a great time so I don't have to deal with that shit.Ehren (52m 45s):And I think that there's the potential for either of that in the festival world, in the commercialized, institutionalized medicalized model, in the coaching model in any of these places. And I think I'm gonna just speak from my own experience as a therapist, like working in a rehab, right? Like I've seen people, you know, substances aside come in and pretend like they're doing the work and just totally diluting themselves and, and we see what that looks like. But sometimes it's easier for people just to kind of pretend like they're going through the steps and the motions and that's what people are ready for and that's okay too. That has to be part of, of the process.Ehren (53m 26s):I've experienced that. I've experienced that self illusion of thinking I'm going somewhere when I'm really just treading water. And there's that, I think it's an important and a natural step actually in any part, right? It's kind of the pre-contemplation part in the stages of change where you have to want to change before you want to change before you change. And I don't necessarily think it's a bad thing that the idea of transformation might be prompted by something like a transformational festival or by the idea of doing therapy or by the idea of whatever modality you're seeking to change with. But yeah, I just get the sense that there's no clear answer to that question around where that line is it's individual and that I'm curious to explore more around like how we've experienced that festival realm and how that might translates into the work we're doing now and what we're seeing in the larger context of, of kind of the rollout of a more mainstream version of psychedelics.Michael (54m 24s):Can I focus this a little bit before I bounce it back to you, Aaron? Because I think, and thank you both for that. One of the, the things that strikes me about all of this is that I think about that classic rat park experiment that, you know, where it showed that laboratory rats don't just by default prefer the cocaine button over food, that there are these un unhealthy addictive patterns are actually, and I talked about this, another expert in unhealthy addictive patterns. Charles Shaw, right? Old friend and complicated figure.Ehren (55m 4s):I love that episode by the way, way back.Michael (55m 6s):She's not way back. Charles is somebody who has been a real pain in the ass to a lot of people over the years, but I think really walks this line now and his, he's, he's gonna mature as a wounded healer into the role of addiction counselor and helping people through these same kind of trials that he himself has been through in his life. And Charles made the point in that I think it was episode 58 or thereabouts, that the addiction is actually the brain doing what it should be doing. Now it's, and I'll be talking about this with some neuroscientists at some point this year also, that the brain, if you think about it as like an uncertainty reduction or free energy minimization, these terms that are floating around now, that the brain is a tool for inference.Michael (55m 50s):And so it likes to be able to make parsimonious predictions about its own future states and about the future of its environment. And in a weird way, addiction facilitates in that. Like when I had Eric Wargo on the show, he was talking about how many people he thinks are precognitive individuals like Harlan Ellison famous science fiction writer who wrote a lot of time travel fiction and has a, you know, that a lot of these people have problems with alcoholism or, or drug use. Philip Kate, Dick, there's a way in which I'm drunk today and I'm gonna be drunk tomorrow, is actually doing, is the brain doing what it's been tasked to do? So there's that on one piece. And then the other piece is that the rat park thing, when at that experiment, when you put rats together with one another in an environment that allows a much more so like a greater surface area for social encounters and more exercise and so on, that they actually prefer the company of other rats and quote unquote healthy behaviors over these repetitive self stimulating addictive behaviors.Michael (56m 57s):And I look at the last few years and how covid in particular seems it the lockdowns people getting stuck in their home for months at a time, the uncertainty of a, a really turbulent environment, the specter of these an ever tightening cinch or vice of government interventions or just the fear of people being as hats and not doing socially responsible behaviors as a res, as a reaction to this crisis. I mean there's just like all of these ways that that mental health has come to the foreground through all of us going through this collective trauma together.Michael (57m 42s):And like we were, Aaron and I were talking about before the call started, the living in Santa Fe in New Mexico, in a place that is so much of its character is about it being a concentration of indigenous people living on reservation, trying to make their way in, in community with wave after wave of European colonists that matters of we're like this relationship between oppression, trauma, substance abuse, or addictive behavior. It's all really interesting. And like the last piece I'll stack on this is when I had Tyson Yoko on the show and Tyson talked about how that this kind of pattern is not unique to peoples that have a very centuries long history of abuse and oppression.Michael (58m 31s):There is, you see opioid crisis coming up very prominently in Pennsylvania, coal mining communities whose way of life has been disrupted by changes in the energy sector by, by massive motions in the world market. And so suddenly you have lots of alcoholism and Oxycontin and fentanyl abuse and so on in, in these places as well. I mean, I guess Daphne especially curious in your sense, you know, in, in this relationship with you're thinking on transgender matters issues, this thing about this relationship between, like you said earlier about getting yourself out of the cage of a particular maladaptive model of self and the way that's related to getting oneself out of the cage of one's condition, like the actual material conditions of one's life.Michael (59m 25s):Because again, just a last callback to another episode, it, the episode I had with Chris Ryan who his book Civilized to Death, he talks about how far we've gone in the modern era from kind of environment that is actually good for the human body and the human mind and how, you know, the covid being a kind of apotheosis of that, of everyone living almost entirely in, in these digital spaces or being forced through economic concerns to work in very dangerous environments without adequate protection. So I mean, I just, yeah, a yarn ball of stuff, but really curious about this, and I feel like you've both addressed some of this already, but just to refocus on this particular corner of it, the way that, you know, addictive behaviors and abusive patterns seem to be the result of structural issues and that the self is also something that emerges out of a dynamic and relational set of feedbacks with that environment.Michael (1h 0m 43s):And so who you are is a kind of reflection of or ever-evolving trace fossil of the world in which you find yourself. And so like when people talk about getting over trauma, like one of the, one of the big, the three main things that people talk about are again and again and all of them find some sort of foothold in or expression in various psychedelic practices. But one is service, one is creative work writing or inquiry, right? Autobiographical writing especially. And then one is travel or pilgrimage and there's a way in which the psychedelic ceremonial container can facilitate anyone or all three of those.Michael (1h 1m 27s):But yeah, I mean it just strikes me that like more, as more and more people come out as neurodivergent or come out as trans in some way or another, or are trying to maintain their sanity in a set of socioeconomic circumstances over which they have no control, that there's something that comes into light here about the way that we're no long like in a, I don't know, I put it like self-discovery of our parents' generation of the second wave of psychedelics in the west was in its own way more about breaking free of the strictures of squared dom, but had an emphasis on much like it was part and parcel with this other thing that was going on, which was this proliferation of lifestyle consumerism.Michael (1h 2m 20s):And Charles Shaw and I talked about that too, about the way that these drives for transcendence were co-opted by finding yourself, meaning settling into kind of understanding rather than a phase change into a more plural or multidimensional or metamorphic understanding of the self. And especially in a regime of extremely granular and pervasive and pernicious behavioral engineering empowered by digital surveillance technologies. It strikes me that there's something that Richard Doyle has talked about this, that like psychedelics are kind of a training wheels for the Transhuman condition and for what it means to live in a network society where you may not actually want to settle on an identity at all.Michael (1h 3m 9s):You know that the identity itself is the trap. So I don't know, I don't know. I thought I was focusing things, but I just blew it up into, anyway, I'd love to hear your thoughts on that particular matter.Ehren (1h 3m 20s):I'll speak briefly to just that notion around connection and social in the Rat Park piece. I mean there's a reason why any type of addiction therapy is like the gold standard is group therapy and why AA groups and all these things, despite their problems still are so popular is because getting connected with community and people that actually understand you is probably the most healing thing out of anything more mu, I mean, working through trauma is important, but having a network of people that you can call and be in relationship to is what I've seen to be the most healing thing for people. And it actually brings up this revision of what I was saying before in a way around the transformational festivals where in retrospect, the most transformational thing for me about those spaces I was inhabiting for so long are these sustained continued connections that we have now with each other, right?Ehren (1h 4m 15s):And like that's where the real magic was actually gaining these deeper relationships with people who understand us. And I think when we look at oppression and look at the systems that prevent people from feeling like it's okay to be who they are, or that there's an inherent shame in the case of trans people or inherent fear of being seen or in the case of economic disparity that like you are stuck in this place and you're going to be stripped and taken advantage of and there's no way out, right? It's a very disconnecting, isolating thing. And even though there can be these pockets of connection between people that are continuously stuck in poverty or contin, continuously stuck in a sense of, as a trans person, I'm constantly being repressed and targeted and there is community in that very often the most healing thing that's needed is to actually integrate back into culture and to change the systems that are creating that disconnection and oppression in the first place, right?Ehren (1h 5m 26s):And it's this open question right now for me in terms of when we're talking about substance abuse, like those communities are breeding grounds for it because that's the way people deal. That's they're, they work, right? Substances work. That's why people use them. And I always look at it like there's nothing wrong with you for going with a strategy that works, but when it comes to psychedelics, what you're saying I think is really important around how do we actually integrate this into an understanding of how we are interconnected with other people and that our own personal work needs to include a justice component or a component of social change or influencing other people's healing to other people's place in the world.Ehren (1

Interested in the potential health benefits of psilocybin, one of the active ingredients in ‘magic mushrooms'? On this episode of The Liz Earle Wellbeing Show, Liz takes a deep dive into the world of psilocybin therapy with Dr Ekaterina Malievskaia.Ekaterina shares the personal story that led her to co-founding mental health care company, Compass Pathways, and discusses the early findings of their clinical trials and studies on psilocybin.Liz and Ekaterina also cover the potential benefits of psilocybin therapy for mental health issues, such as depression, PTSD and anorexia.Links mentioned in the episode:Visit the Compass Pathways websiteView the Compass Pathways' findings of psilocybin for treatment-resistant depression here Listen to our podcast with Mary Biles on medical cannabisListen to our podcast with Avrum Bluming on oestrogenSubscribe to Liz Earle Wellbeing Magazine Hosted on Acast. See acast.com/privacy for more information.

Annalisa Jenkins, MBBS, Non Executive Director at Compass Pathways & Jim Weiss, Founder and Chairman at Real Chemistry, join the podcast this week to discuss women in life sciences leadership roles, novel approaches to disease areas such as infectious diseases and cancer, and using AI for a more effective healthcare system.

Another installment in one of our ongoing pathways of contemplation: How to bring a little more wisdom, love, and beauty into our work with the medicines of this world.In this episode, Sunny Strasburg, LMFT joins us to discuss ketamine, magic, and more.Sunny Strasburg, LMFT is a psychedelic trainer, consultant, therapist, and presenter. Mrs Strasburg is an EMDR-certified trauma specialist, experienced and certified in psychedelic-assisted psychotherapy, and trained in Internal Family Systems. Mrs. Strasburg is a graduate of the Certification for Psychedelic Assisted Therapy from the California Institute of Integral Studies, trained in Ketamine, MDMA, and Psilocybin Assisted Psychotherapies. Sunny is the Clinical Director at TRIPP PsyAssist, developing virtual reality psychedelic support for therapists.Sunny offers Ketamine therapy retreats, which she co-leads with Dr. Richard Schwartz, the originator of Internal Family Systems. She is a Senior Trainer at the Ketamine Training Center, co-facilitating KAP training with Bessel van der Kolk, Phil Wolfson, and other leaders in psychedelic and trauma psychology. Mrs. Strasburg also leads psychedelic therapy workshops and trainings around the world.Sunny also specializes in attachment trauma, using an eclectic approach with the Gottman Couples Method and Jungian psychology. She offers Ketamine Assisted Therapy with individual sessions and group therapy retreats.Sunny has developed original protocols using ketamine-assisted therapy and other trauma treatment methods, which she presents at conferences such as the 2021 EMDRIA Worldwide Virtual Conference, EMDRIA UK, and the Boston Trauma Conference. Sunny co-founded the nonprofit organization, Indra's Net Coalition.She is trained by MAPS, Compass Pathways, Ketamine Research Foundation, and Synthesis. Sunny hosts therapy retreats in Utah, Maryland, California, Wyoming, and Costa Rica. You can find out more at https://sunnystrasburgtherapy.com/

Dr. Maysa Alavi, MD is a board-certified physician and internationally recognized speaker, practitioner, and teacher of Psychedelic Therapies, Ketamine Administration, and Integrative Medicine. She unites cutting-edge Western science with Eastern wellness philosophies to heal mind, body and spirit in what she terms ‘Functional-Psychedelic Medicine,' addressing the psycho-spiritual as well as the material.She has studied at best-in-class institutions and organizations including The University of Southern California, University of Texas, UCLA, Institute for Functional Medicine, and Dr. Andrew Weil Center for Integrative Medicine. Dr. Maysa is certified in MDMA Assisted Therapy by the Multidisciplinary Association for Psychedelic Studies (MAPS), and she is trained in psilocybin assisted therapy with COMPASS Pathways.Among her many roles are Study-Site Physician and Therapist for the MAPS Phase 3 Clinical Trials investigating the use of MDMA Assisted Therapy for the treatment of PTSD. She will be among the first providers to bring this form of therapy to the general public pending FDA approval. Dr. Maysa teaches for Fluence in the field of Ketamine Assisted Therapy (KAP) and she conducts small group trainings for medical professionals looking to start their own ketamine practice, teaching the fundamentals of psychedelic preparation and integration, and how to medically screen for and administer ketamine by its various routes. She is a consultant for start-up practices entering the psychedelic market and she serves on the Board of Advisors for the Veteran's Alliance for Holistic Alternatives (VAHA). She has given many lectures on the topics of psychedelics, cannabis, and ketamine for the New Orleans Psychedelic Society and Cultivating Self, a non-profit continuing education platform for licensed healthcare professionals and RNs. Dr. Maysa humanizes health care by developing trusted personal relationships with her clients, empowering them to understand the root causes of their dis-ease and helping them connect with their own inner healing intelligence for long-term wellness. This goes above and beyond typical “symptom management medicine” by identifying and bringing awareness to the issue's origin and its perpetuating and mediating factors.She incorporates multiple modalities into her practice—from functional labs, nutraceuticals and IV infusions to energy work, plant and psychedelic medicines and mind-body techniques. She works with clients to develop balanced healing plans that combine mind-manifesting therapies and advanced laboratory analysis with wellness approaches that nurture wholeness. Her plans include customized guidance on hydration, nutrition, breath-work, meditation, movement, stress-reduction, sleep optimization, supplementation, medication reconciliation and/or tapering for those on pharmaceuticals, and laboratory analysis. She applies her in-depth knowledge of traditional and indigenous plant medicines like psychedelic mushrooms, cannabis, ayahuasca, rapeh, kambo, salvia and sananga by educating clients on the safe and appropriate usage of these and other medicines. Dr. Maysa believes that simple changes yield meaningful results, namely: proper salt/mineral and water balance in the body, utilization of the light/energy spectrum, awareness of breath and optimizing airway and sleep, joyful movement, conscious consumption, and connection with community and one's own inner world. She believes regular reboots of our “inner computer” are critical and can be accessed through mind-manifesting therapies including, but not limited to psychedelics and entheogens (heart openers). She is a huge proponent of daily meditation and Blessing of The Energy Centers. Visit Dr. Maysa's website www.DrMaysa.com for more information about her, her offerings, and to book in-person or remote visits. 

Magic mushrooms are generally associated with the rave scene, or festival goers having a trippy experience. But what if these mushrooms are the future of mental health? Millions and millions have already been poured into research globally to measure the effects of the active ingredient, psilocybin.In this episode of The Next Stage Katerina Mal-eev-ska, co-founder of mental healthcare company Compass Pathways, talks about the exciting new results from her company's psilocybin trial.20 percent of people experiencing what is known as ‘treatment resistant depression' responded to psilocybin despite having not responded for years or even decades to currently approved depression treatments, says Katerina. Keep listening for more details on this groundbreaking new study."The best technology conference on the planet". Join us in Lisbon this November. "The best technology conference on the planet".Follow us on Twitter, Instagram and Linkedin.

The Science Behind The Psychedelics Boom There's been an explosion of new research into therapeutic uses for psychedelics. This includes drugs like psilocybin, the hallucinogenic chemical found in “magic mushrooms,” and ketamine—which was originally used as an anesthetic, and later became a popular party drug also known as “special K.” Esketamine, a form of ketamine, was approved by the FDA in 2019 for use in treatment resistant depression. And just last month Colorado residents voted to legalize medicinal use of psilocybin. Following on the heels of Oregon's legalization in 2020, which is now in the process of being implemented. A recent study published in the New England Journal of Medicine showed promising results in using psilocybin to help patients with treatment-resistant depression. About a third of those who received the highest dose were in remission 3 weeks later. This was the largest look at psilocybin's effect on depression to date, involving 233 participants across ten countries in Europe. Ira talks with Dr. Steve Levine, senior vice president of patient access and medical affairs at COMPASS Pathways, the company that funded the study. Later, Ira takes a closer look into the latest psychedelic research and takes listener calls with Dr. Gerard Sanacora, professor of psychiatry and director of the Yale Depression Research Program at the Yale School of Medicine, and Dr. Alissa Bazinet, Clinical Psychologist, Co-Founder and Director of Research and Development at the Sequoia Center, and Associate Director of the Social Neuroscience and Psychotherapy Lab at Oregon Health and Science University.     How Will AI Image Generators Affect Artists? Back in August, controversy erupted around the winning submission of the Colorado State Fair's art content. The winning painting wasn't made by a human, but by an artificial intelligence app called Midjourney, which takes text prompts and turns them into striking imagery, with the help of a neural network and an enormous database of images. AI-based text-to-image generators have been around for years, but their outputs were rudimentary and rough. The State Fair work showed this technology had taken a giant leap forward in its sophistication. Realistic, near-instant image generation was suddenly here—and reactions were just as potent as their creations. Tech enthusiasts lauded the achievement, while artists were largely concerned and critical. If anyone could make a painting in just a few seconds, why would someone need to commission an artist to produce an illustration, or even bother spending years learning art at all? Read the rest on sciencefriday.com. Transcripts for each segment will be available the week after the show airs on sciencefriday.com.  

On this edition of Parallax Views, in the first segment Wall Street Window's Mike Swanson returns to the program to discuss the FTX/Sam Bankman-Fried crypto scam scandal as well as Elon Musk's buy out of Twitter. Among the topics covered in the course of our conversation: - Sam Bankman-Friedman, Alameda Research, Bankman-Fried's apology letter and his claim that what happened with FTX was a bank run, and whether what happened was a case of an inside job fraud or not - The high-risks involved in the crypto exchange; how these crypto exchanges aren't banks and are not regulated in a meaningful way; the damage that the FTX scandal has done to people - Relating past events like the Enron and WorldCom scandals and the the stock market's Dot-Com Bubble of the 1990s to the present day - The influential American venture capitalist firm Sequioa Capital and the FTX scandal; Sequioa Capital's failure in relation to the FTX scandal is symptomatic of a bigger problem; firms not wanting to miss out on the hot new "Thing" or fads - Reports that Sam Bankman-Fried ran FTX as his own personal fiefdom - The political Left, the political Right, and the economy - The divide in the Libertarian movement over crypto currency - Karl Marx, Peter Thiel, and the possibility that the capitalist system itself is producing too much capital in ways that drive down interest rates; the issue as being more than the Fed just making mistake (ie: a problem with how the 21st century capitalist system itself operates currently); new money influxes as slowing down the bear market - The lowering of interest rates and the creation of bubbles - Jacob Silverman and Ben McKenzie's upcoming book Easy Money: Cryptocurrency, Casino Capitalism, and the Golden Age of Fraud; elements of the libertarian world agreeing with leftist critiques of crypto currency arguing that it's just a bubble or scam - Gold and silver, the stock market, Robin Hood, and "meme stocks" - Younger people becoming wary of stock trading - Elon Musk's buying of Twitter for $44 billion; Musk wasn't able to back out of the deal; Twitter losing money - Meta, Facebook, the Metaverse, and Mark Zuckerberg losing money; the layoffs at Twitter, Facebook, and Amazon - Casino capitalism, carny tricks, and social media misleading people on issues like crypto - Social manias, the madness of crowds, financial bubbles, and not falling for hype In the second segment of the program, Daniel Pinchbeck, author of a number of books on psychedelics including most recently (w/ Sophia Rokhlin) When Plants Dream: Ayahuasca, Amazonian Shamanism and the Global Psychedelic Renaissance, joins the show to discuss his recent WhoWhatWhy article "Why Psychedelic Capitalism Sucks". Among the topics we cover in this conversation: - The rise of psychedelic corporations/psychedelic start-ups - The demonization of psychedelics in the 1960s and the cultural thaw that's led to a psychedelic renaissance through groups like MAPS and the Beckley Foundation; the reconsideration of psychedelics by society today and contemporaries studies on psychedelics related to alleviating depression, etc. - Festivals like Burning Man and how resource-rich elites and entrepreneurs became interested in psychedelics - Predatory practices and the critique of patents in regards to psychedelics and psychedelic therapy - Compass Pathways and patent laws - Downsides of psychedelics and psychedelic use - The ecological crisis, today's profound social inequality, and psychedelics as a way to inspire social and structural change - The contemporary psychedelic movement's focus on medicalization that fits psychedelics - Psychedelics, creativity, and pattern recognition - Psychedelics, temporary bliss states, and a possible 1984/Brave New World scenario - Pioneering psychedelic researchers Sasha and Ann Shulgin's approach to psychedelic research vs. the approach of psychedelic corporations - Psychedelic use and messianic delusion - The positives of psychedelics and psychedelic usage - The question of consciousness - The climate change crisis and transforming how we live our lives; the importance of storytelling - Shifting away from industrial agriculture - And much, much more!

On November 3rd, the "Wonderland Miami" psychedelic conference banned the entire Psymposia team from the event. Compass Pathways consultant Hamilton Morris then took to the stage to distort and misrepresent our research. This podcast was edited for clarity from a YouTube livestream recorded on November 15, 2022.   Watch it here: https://youtu.be/ckxKJQedx1c   If you're not terminally online, here's a bit more context: Psymposia's Twitter rundown Dr. Brian Pace's Twitter rundown Wonderland Miami Exposes Growing Rift in Psychedelic Community, by James Kent     Support the show:   ☼Patreon: http://patreon.com/psymposia ☼Donate: https://www.psymposia.com/donate/         Follow:   ☼Twitter: https://twitter.com/psymposia ☼Instagram: https://www.instagram.com/psymposia/ ☼Facebook: https://www.facebook.com/psymposia ☼Twitch: https://www.twitch.tv/psymposia ☼Website: https://www.psymposia.com ☼Podcast: https://www.psymposia.com/plusthree ☼Newsletter: https://www.psymposia.com/subscribe/

In this week's episode, we chat with Christian Angermayer. Christian co-founded atai Life Sciences and was an early investor in Compass Pathways -- two of the first companies commercializing psychedelic medicine. Christian also launched a fund dedicated to mental and neurological health called re:Mind, is an investor through his family office Apeiron, and co-founded two longevity biotech companies.Credits: Created by Greg Kubin and Matias SerebrinskyHost:  Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank

Straight from Benzinga newsdesk, host Brent Slava brings you the market news and stocks to watch.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659Hosts:Brent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga Newsdeskpro.benzinga.com$NVDA $ZM $BFAM $CMPS $BBIGNVIDIA (NVDA) - Will report quarterly results Wednesday next week. The company will likely report its earnings around 4:20 p.m. EDT.Zoom Video Communication (ZM) - The company will publish quarterly results on Monday, Aug. 22, 2022 after market close.Bright Horizons Family Solutions (BFAM) - An interesting play on the work from home trend. Morgan Stanley discussed the company and stock in a research note Thursday morning. Analysts at the firm called Bright Horizons shares their highest-conviction recommendation to gain some bearish exposure. To hear more details from the Morgan Stanley call, tune into Benzinga's daily Stocks To Watch podcast around 9:30 a.m. EDT on Twitter or after 10 a.m. on Spotify or Apple.COMPASS Pathways (CMPS) - A play on psychedelics. Shares of peer in the psychedelics space, MindMed (MNMD), traded up about 70% in pre-market action. The Benzinga Pro newsdesk team did not identify news to justify the move higher in MindMed. Shares of MindMed and COMPASS Pathways have been known to trade relatively correlated.Vinco Ventures (BBIG) - A favorite among the Benzinga Pro user community. Shares have more than doubled so far this week following news Monday of a partnership with AIPros for social media. Momentum has continued each day following the news.Use coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this special episode of “Everyone has a story: talking about mental health”, COMPASS Pathways' Co-founders, Ekaterina Malievskaia and George Goldsmith, chat to Kabir Nath, newly appointed Chief Executive Officer from 1 August 2022, and former Senior Managing Director of global pharmaceuticals at Otsuka Pharmaceutical Co., Ltd. Kabir talks about his story, his new role, and making COMPASS's mission a reality.

Something crazy happened in this episode: young people actually dropped some knowledge on us for this Youth Day special on investing. Youngsters are evolving and we love it!We'd like to introduce 19-year-old twins, Connor and Justin Stubbs, who are owning the markets while also educating their peers on investing and finance.The twins highlight how they navigated around the complicated jargon and terminology that is saturated in the finance industry, as well as sharing some of their personal lows and highs as investors with a particular love for crypto.We also get into the minds of teenagers to understand their personal strategies and investment goals. Their long-term goals shine a light on why they're keeping their eyes on Berkshire-Hathaway and Compass Pathways. Listen to this episode to check out their insights on these shares and more!If you're a minor or know of any minors that would love to invest, make sure to head on over to this page to be like Warren Buffett and the Stubbs twins by investing early. The kids will be alright.Share the love with us on social media by letting us know what you think of the episode by tweeting @EasyEquities @YoungInvestor03 @GenZInvestor4 or tagging us on the gram.To sign up to EasyEquities: http://bit.ly/2EtcE85DISCLAIMER: EasyEquities is a product of First World Trader (Pty) Ltd t/a EasyEquities which is an authorised Financial Services Provider. FSP number: 22588. This material is not intended as and does not constitute financial advice or any other advice and is neither exhaustive nor prescriptive. The views expressed by the contributor are his or her own (as an independently registered financial services provider, financial adviser or other independent capacity), and not necessarily endorsed by EasyEquities (as a separate financial services provider).

America faces a mental health crisis. Problems with mental health care preceded the pandemic, but over the past two years we've seen these problems grow into a crisis as young people were more likely to die from deaths of despair than from COVID-19. This presentation describes the path to solve this mental health crisis. Dr. Tom Insel says part of the solution involves fixing the care system—moving from a crisis-driven sick-care system to a comprehensive, continuous health-care system. Innovative technology will be part of this fix. So will innovative policy. But mental health is about more than mental health care. Insel says the path to mental health requires a focus on recovery defined by the 3 P's: people, place and purpose. Join us as Insel urges that we reframe our approach to mental illness, recognizing that the problem is medical but the solutions are social, environmental and political. Show editorially warning About the SpeakerTom lnsel, M.D., a psychiatrist and neuroscientist, has been a national leader in mental health research, policy and technology. From 2002–2015, Dr. Insel served as director of the National Institute of Mental Health (NIMH). More recently, he led the Mental Health Team at Verily (2015–2017); co-founded Mindstrong Health (2017–2019), a start-up building tools for people with serious mental illness; and served as a special advisor to California Governor Gavin Newsom (2019), helping on behavioral health issues. In 2020, he co-founded Humanest Care, a therapeutic online community for recovery. He currently serves on the boards of Foundation for NIH, Fountain House, Schaeffer Center for Health Policy, and the Steinberg Institute (chairing it from 2019–2022), as well as being an advisor to several mental health start-ups (including Alto Neuroscience, Cerebral, Compass Pathways, Owl Insights, Koa Health, Valera Health). He is the author of Healing: Our Path from Mental Illness to Mental Health (Penguin Random House, 2022). With journalist co-founders, he recently launched  Show editorially warning MindSite News, a nonprofit digital publication focused on mental health issues. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe. More info at  Show editorially warning his website.MLF ORGANIZER Patrick O'Reilly SPEAKERS Show editorially warning Tom lnsel M.D., Psychiatrist; Neuroscientist; Author, Healing: Our Path from Mental Illness to Mental Health Show editorially warning Patrick O'Reilly Ph.D., Clinical Psychologist; Assistant Clinical Professor, UC San Francisco; Chair, Member-Led Psychology Forum—Moderator In response to the COVID-19 pandemic, we are currently hosting all of our live programming via YouTube live stream. This program was recorded via video conference on May 31st, 2021 by the Commonwealth Club of California. Learn more about your ad choices. Visit megaphone.fm/adchoices

Otsuka Pharmaceuticals is expanding its mental health formulary – looking beyond traditional medications to psychedelics, and to the “intersection of technology and psychiatry” with digital therapeutics currently in clinical trials for Major Depressive Disorder. Kabir Nath, Senior Managing Director of Otsuka's Global Pharmaceutical Business, lets us in on the thinking behind these bold moves, why the pharma co is even innovating to expand the spectrum of treatments available for mental illness in the first place, and how soon these new therapies will reach patients. “Follow the science” is a key undercurrent of this conversation, particularly as we talk through Otsuka's investments in psychedelic medicine start-ups Compass Pathways and, more recently, Mindset. Kabir says the body of clinical evidence for these therapies is building and we get his prediction on when they might become more mainstream and readily available. We also get his take on digital therapeutics (DTx) and the work Otsuka is doing with Click Therapeutics in Major Depressive Disorder. Their clinical trial, done in partnership with Verily, is the first-ever fully remote clinical trial conducted in this space, and the hope is that it not only generates evidence to support the emerging DTx category, but that it also sets a precedent for a new, tech-enabled way to run clinical trials. This is just the beginning. There's lots more on the innovations changing pharma and the future of mental health care in this one. Watch now! Jessica DaMassa, the emerging ‘It girl' of health tech interviewing, chats it up with the ‘who's who' of the health tech and healthcare innovation set on 'WTF Health - What's the Future, Health?' Catch 100's of interviews with leading health tech startups and the VC investors, health insurance companies, big pharma co's, and hospital systems helping bring their new ideas into the healthcare establishment. From AI and Big Data to digital health, virtual care, telehealth, digital therapeutics, payment model innovation, and investing, Jessica helps you spot the trends and figure out what's next.

Brom Rector, Founder, and GP of Empath Ventures. Prior to founding Empath, Brom spent 7 years as a portfolio manager and quantitative researcher - most recently managing a global macro portfolio for Crabel Capital Management - a Los Angeles-based hedge fund with $8B AUM. After leaving Crabel in 2020, Brom started The Integration Conversation, a long-form video podcast that covers the psychedelics industry from an investing perspective. The research that went into this podcast and the connections it established laid the groundwork for what would become Empath Ventures. On this episode, Brom gives a breakdown on the breakdown of the Psychedelic industry and landscape. They discuss why Brom raised a fund to target psychedelics and how he's investing the money and why it's one of the largest opportunities in the world. Listen to hear Brom's thoughts on what the next 10 years of psychedelics might look like and much more! Follow Chris on Twitter: www.Twitter.com/FortWorthChris  Follow Chris on LinkedIn: www.linkedin.com/in/chrispowersjr/  Subscribe to The Fort on YouTube: https://www.youtube.com/channel/UCuJ32shRt8Od3MxMY-keTSQ Follow The Fort on Instagram: www.Instagram.com/TheFortPodcast (01:56) - Brom's Background and Career in Psychedelics Empath ventures (07:22) - Why have psychedelics been illegal and shunned from society? (11:28) - What's Big Pharma's role in this? (12:49) - What is the chemical reaction happening inside the body when one takes psychedelics? (14:38) - Are all psychedelics man-made or are there any occurring in nature? (16:03) - How far back do psychedelics go in human history? (17:20) - How big is this industry from an economic standpoint? Data on funding trends in psychedelics:  https://www.cbinsights.com/research/psychedelic-therapies-funding-startups/ (20:09) - How do we define what is legal and illegal in the psychedelic space? (22:16) - Does FDA approval make it legal or does there need to be a law passed? (22:54) - What needs to happen for the FDA to change their minds on psychedelics after all these years? (24:16) - Would these drugs displace other opiate treatments? (25:25) - The Hype Around Psychedelics in Society (26:42) - What parts of the industry interest you the most? (28:52) - Thoughts on Micro-Dosing (30:14) - Advancements in ways to “stop” the trip (31:31) - Brom's Personal Experiences with Psychedelics Compass Pathway studies (33:48) - Integration Therapy (34:59) - Do you do any pre-planning or set intentions for psychedelic experiences? (37:29) - Empath's intentionalities: Receptor Targets, Indications, and Time to Market (41:04) - What does an early-stage psychedelic company look like? (42:26) - What becomes the IP in these companies? (44:07) - Compass Pathways  Freedom Bioscience Partners (45:43) - The Different Experiences from Different Psychedelics (47:25) - Data on effects of psychedelics on minors (49:12) - At what point is testing introduced on humans for new psychedelic molecules? (51:07) - What's going to happen in this space over the next decade? Wavepaths music (56:30) - Is there any merit in psychedelics as a preventative? (1:00:07) - What's happened to the brain of people who become depressed? (1:02:01) - What do you predict to be the first mainstream psychedelics? (1:03:25) - How is Oregon doing since decriminalizing drugs? (1:04:01) - How can people track the progress of clinical trials and legislation? (1:04:43) - Wrap Up & Contact Brom on Twitter Empath Ventures The Integration Conversation podcast The Fort is produced by Johnny Podcasts

A good leader sets the tone for an organization. Without good leadership, employees won't know the right direction to take or what they can improve upon. While men and women may generally have different needs and motivations, the qualities that make a good leader are the same for both. What is also important and needed for all leaders to succeed is to continuously seek out next level mentors with fresh perspective so they don't get caught up in their own echo chamber and get left behind. Dr. Annalisa Jenkins, M.B.B.S., F.R.C.P. is a biopharma thought leader and a board member for several growing companies. She shares with us her experiences, from the British military to the boardroom, and what it's been like to work in this age of life science innovation and digital advances. Coming from a generation where male mentors were common, Dr. Jenkins speaks about working as a woman in her industry and how she's learned to be a “tough but fair” leader under their direction. Her broad array of experiences in health sciences shows us how to bring vision to our workplace as leaders. Visit https://www.iambeyondbarriers.com where you will find show notes and links to all the resources in this episode, including the best way to get in touch with Annalisa. Highlights:  [02:27] Annalisa's global background [05:09] Annalisa's career goals [08:08] What five things make a successful leader [13:35] Is there a difference between male and female leaders? [16:08] Other important qualities of a leader in the workplace [19:52] Identifying potential leadership mentors [29:21] Coping with division created by making decisions [35:19] The importance of feedback and not taking it personally  [42:38] Working in the age of life science innovation and digital age  [46:56] Identifying the waves that affect your industry [50:51] What book has greatly influenced Annalisa? [51:47] Annalisa's favorite quote [52:50] Annalisa's moniker to describe herself [53:19] One habit that makes a big difference in Annalisa's life [55:00] Annalisa's power song [56:41] How to connect with Annalisa Quotes: “Great leaders have a clarity of vision.” –  Dr. Annalisa Jenkins “People that can bring teams together and get them to collaborate are always going to be successful.” –  Dr. Annalisa Jenkins “Great leadership comes from those who are willing to lean in and take decisions.” – Dr. Annalisa Jenkins Lightning Round Questions: What book has greatly influenced you?  Who Says Elephants Can't Dance? By Louis V. Gerstner, Jr. What is your favorite inspiring quote or saying?  “Live the life you love and love the life you live.” What is one word or moniker you would use to describe yourself?  Gracious What is one change you've implanted that made your life better?  Carving out two hours every morning to go to the gym. To think, reflect, prepare myself. It creates mindfulness. What power song would you want playing as you walk out onto a stage?    “Paradise” by Coldplay, the song and video. About Dr. Annalisa Jenkins: Annalisa Jenkins, M.B.B.S., F.R.C.P. is a biopharma thought leader with over 25 years of industry experience. Dr. Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems around the world. In addition, she is an advocate for diversity and inclusion, particularly for women in science. Dr. Jenkins served as president and CEO of Dimension Therapeutics a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior senior leadership roles have included the head of global research and development at Merck Serono Pharmaceuticals from 2013 to 2014, where she also served as executive vice president global development and medical from 2011 to 2013 and several leadership roles at Bristol Myers-Squibb (BMS) from 1997 to 2011, most recently serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew's Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.  Dr. Jenkins is a board member of several growing companies, including Oncimmune, AVROBIO, COMPASS Pathways, AOBiome, AgeX, Phaim Pharma, Conduit Connect, Affimed, Genomics England, Blue Advent Ltd, Cocoon Biotech Inc. (Non-Executive Chair), and Kuur Therapeutics (Non-Executive Chair). She also is a medical trustee for the British Heart Foundation and a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues, board member at Faster Cures a center of The Milken Institute and Chair of The Court of The London School of Hygiene and Tropical Medicine.  Additional appointments reflect Dr. Jenkins' commitment to advancing the opportunities of women in science and the need for new models of health care in resource poor settings. She serves on the boards of Women in Bio, an organization promoting careers, leadership, and entrepreneurship for women in the life sciences, and the Center for Talent Innovation (U.K.), dedicated to driving ground-breaking research that leverages talent across gender, generation, geography, and culture. She also is an executive committee member of Springboard Enterprises, and is on the Advisory Panel of the Healthcare Businesswomen's Association, which elected Dr. Jenkins as Woman of the Year in 2014. She co-founded and serves on the board of directors of YouBelong, a UK based charity developing and delivering new models of care to people currently living with mental health diseases and incarcerated in institutions in sub Saharan Africa.  Links: Websites: LinkedIn: https://www.linkedin.com/in/annalisajenkins/ Instagram: https://www.instagram.com/jenkinsannalisa

As the lead investor in Compass Pathways, Founder of Atai Life Sciences and Apeiron Investment Group, Christian is the perfect person to talk everything psychedelics in 2022. With a diverse portfolio across Fintech, Crypto, Life Sciences, Media, Entertainment and more, Christian is a true leader in spotting unique business opportunities and driving these organisations forward. Tune into Christian's interview today!Take a look at the full collection of podcasts and explore additional cannabis & psychedelics content on the GCI Content Hub: https://contenthub.gcintelligence.com/ 

In this week's pod we examine Business Insider's attempted takedown of media mogul Dave Portnoy and why we're buyers of Penn Gaming (6:39). We also review Grizzle conviction calls (29:24): Dutch Brothers, Compass Pathways, Airbnb, Arc Resources & Range Resources. We cap off the episode with an analysis of software growth rates vs. share price performance (50:25); and a postmortem on Peloton's ugly quarter (56:23). Charts for this episode can be found here: https://youtu.be/7PLPkMB-0Sw Grizzle Pod is brought to you by our friends at ycharts.com

Ekaterina Malievskaia MD, is Co-founder and Chief Innovation Officer of COMPASS Pathways (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia, and then moved to the US where she completed her Internal Medicine residency training. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at the City University of New York. After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member. FIND EKATERINA ON SOCIAL MEDIA LinkedIn ================================ SUPPORT & CONNECT: Support on Patreon: https://www.patreon.com/denofrich Twitter: https://twitter.com/denofrich Facebook: https://www.facebook.com/denofrich YouTube: https://www.youtube.com/denofrich Instagram: https://www.instagram.com/den_of_rich/ Hashtag: #denofrich © Copyright 2022 Den of Rich. All rights reserved.

Caring for cancer patients should include their mental as well as their physical health. COMPASS Pathways' Ekaterina Malievskaia talks to Manish Agrawal, medical oncologist and co-director of clinical research at Aquilino Cancer Center in Maryland, an outpatient community centre dedicated to whole person cancer care. In 2020, Manish was part of the team that built the Center for Healing at Aquilino, designed to address the emotional toll of cancer on patients and caregivers. Manish is now in the final stages of an FDA-approved clinical trial in psilocybin therapy for cancer patients with depression, the first of its kind. In the trial, patients are given psilocybin, a psychoactive substance, while supported one-to-one by a specially trained therapist, with preparation and integration sessions before and after the psilocybin session. Manish talks about the promise of psilocybin therapy as a tool to help patients overcome the distress that comes with a cancer diagnosis, and the impact that this has on him personally, as well as on his patients and their families.

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.In this episode, we discuss:Lars' experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways' Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested inLinks to topics discussed in this episode:Compass Pathways, Lars WildeCOMP360SSRI, SNRIChristian Angermayer, Robin Carhart-Harris, Michael PollanVivaneoQuercis PharmaTRD (Therapy-Resistant Depression)Compass Phase 2B TrialJazz PharmaceuticalsCompass Pathways 2 US patentsOregon Psilocybin Therapy Measure 109Read the transcript here.Watch episode 10 on YouTube.Created by Greg Kubin and Matias SerebrinskyHosts: Matias Serebrinsky and Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: River Meditation by Jason Shaw and Thea by Muted Circus

Episode discussion topics We're on the hunt for solutions and having access to the solutions of our choice. The natural world is full of problems and more importantly, solutions to these problems. Natural remedies have been time-tested through the processes of evolution and natural selection and deserve our attention. Go for a swim! "Regular swimming has been shown to improve memory, cognitive function, immune response, and mood. Swimming may also help repair damage from stress and forge new neural connections in the brain." Psilocybin is a champ when it comes to relieving the symptoms of both depression and anxiety. In fact, things are starting to move fast in the world of studies on the drug. Researchers' appetites were made wet back in 2016 when a ground-breaking study at the time showed that a single dose administered under the care of psychiatric medical doctors provided relief from depression in cancer patients for years. As recently as November 2020, John Hopkins University School of Medicine produced a study that shows even more remarkable promise for this brain wonder drug, quoted below: “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” says  Alan Davis, Ph.D.,  adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. “Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard' placebo-controlled clinical trials.” Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows. More than that even... This article from Nature mentions treatments for PTSD in addition to the others we already covered. What's also notable in this article is a nifty little table that shows the number of studies being undertaken in recent years on this subject. 2020 was a boom year with 17 studies including 13 focused on Psilocybin, 3 featuring MDMA (a.k.a Molly or Extasy), and 1 on good old LSD. Now those last two we're not so sure how natural they are, for the record. The chart goes back to 2010, so check it out if you like infographics. One timely piece on this subject comes to us from the New York Times and provides some of the business going on behind the scenes,  "Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences." Just as the subheading suggests, it will be interesting to see what comes in the wake of all these newly destabilizing forces that might upend the mental health industry and have far-reaching implications for ending prohibition by the U.S. Federal Government. Here's a quote that shows how quickly things are moving now... "More than a dozen start-ups have jumped into the fray, and the handful of companies that have gone public are collectively valued at more than $2 billion... Compass Pathways, a Nasdaq-listed health care company that has raised $240 million, is conducting 22 clinical trials across 10 countries of psilocybin therapy for treatment-resistant depression." Addiction is an issue all on its own, complex and varried. No specific type of consumption is more or less addictive to people who have "non-addictive" personalities. Those people should be free to have choices. Yes, relatively among the things that people get addicted to, some are more addictive than others and it is also true that "old habits die hard." However we must also consider that when people can be addicted to food, alcohol, narcotics, opioids, sex, etc. what is most addictive, is the escapism that these experiences offer in place of a truly fulfilling life. A truly fulfilling life is one when you go to bed and fall asleep fast because you're excited to wake up in the morning. Not because it's Christmas, but because you're alive and you have something left to do to which you're looking forward to finishing. Call to Action: At Citizen Do Good, we believe that increasing access to choices helps to fuel our freedom of choice!  Let us not only trust in the very young, very astute scientific method but also the age-old wisdom that comes from generations of exploring nature for ourselves - experientially.  After all, we knew as a matter of fact, before science, that mother's milk is way more nourishing than any substitute we can concoct. Make an informed opinion by learning more now. Use some of the resources we've shared and consider exploring how you might gain more awareness experientially if such an opportunity arises. One of the most critical components of all these studies is that people feel comfortable relying on doctors, it feels safer and that's a key. You should ensure you have a trusted, safe, and secure environment any time you explore new things - unless you're climbing Everest. Even then, you'd be relieved a bit by having a guide, solid equipment, and some training or practice ahead of time. Hopefully, this analogy makes sense. What about the law? Similar to how marijuana is being made legal state by state in American fashion, an end to the prohibition on other schedule 1 substances will likely be won state by state at the ballot box or through legislatures. That's what we do in our Republic absent of major pressure in D.C. by unseen forces. Someone at Bloomberg agrees with this assessment. In contrast, a somewhat more hopeful tone is coming from Rolling Stone who attempts to answer the question of whether the current Democratic majority will pick up the mantle. Case in point, as of July 2021, California's legislature is working up a bill to do just that: California advances decriminalizing psychedelic substances. So at least the states are getting on the move and like Marijuana back in the 1990s, it looks like the west coast is on the cutting edge. Your hosts: Michael V. Piscitelli and Raymond Wong Jr. More info The war on drugs ended up being a war on Americans. It was good for business and white supremacy. NPR has a timely series named, "The War On Drugs: 50 Years Later," dedicated to providing more perspective in this space. What about Marijuana? We haven't highlighted it because now 37 states have some form of legalized access to this gateway drug. Gateway to legalization and decriminalization for all the inmates on the Federal Schedule 1 drug row.  As far as medicine, it definitely can help overcome a lack of appetite and help insomniacs get some sleep. I don't think we need to consult medical advice to know that's true. Prohibition (the alcoholic one) - we will need to do an episode on just this and the IRS. Coming soon. Gene Editing - also another episode we promise to bring you in the future. In short, it seems like CRISPR-CAS9 isn't the only game in town. More to come. Please feel free to share your thoughts through our Contact Us page or on Facebook. Learn more and reach out Head to Citizens Prerogative for additional information and log in or sign up to leave a comment. Don't forget to join our free newsletter and get 10% off at our shop! Go the extra mile by supporting us through Patreon. Please contact us with any questions or suggestions. Special thanks Our ongoing supporters, thank you! Our sponsor CitizenDoGood.com. Graphic design by SergeShop.com. Intro music sampled from “Okay Class” by Ozzy Jock under creative commons license through freemusicarchive.org. Other music provided royalty-free through Fesliyan Studios Inc. 

Christian Angermayer is one of the world's leading investors in psychedelics. Christian invested in the seed round Compass Pathways and recently founded Atai, a multi-billion dollar publicly traded psychedelics company. Christian talks about his beginnings, and how they led him to his current project: Atai Medical. ––– LUKKA Lukka Prime is crypto asset pricing data aligned to accounting standards like GAAP and IFRS. Lukka Prime Pricing Data is the pricing source used by S&P Dow Jones Indices' for their new cryptocurrency indices. Lukka Prime is the world's first fair market value pricing source for crypto assets and the best option for all post-trade reporting needs. Visit lukka.tech/empire to learn more. ––– Get unparalleled access to the greatest minds in macro at Blockworks' three day, executive summit in Bretton Woods. August 11 - 13. Apply to attend today! https://blockworks.co/brettonwoods/empire --- Empire is brought to you by Blockworks, a financial media brand delivering breaking news and premium insights about digital assets to millions of investors. For more content like Empire, visit http://blockworks.co/podcasts. Follow me on Twitter @JasonYanowitz and let me know what you thought of the show!

My guest this morning is Countess Amanda Feilding – the Founder and Executive Director of the Beckley Foundation – widely recognized as a leading force behind the current Psychedelic Renaissance.Born in 1943, Countess Feilding is the youngest child of Basil Feilding, great-grandson of the 7th Earl of Denbigh and the Marquess of Bath, and his wife and cousin, Margaret Feilding.She has propelled the field forward over the last 20+ years, spearheading studies such as the world's first psilocybin for treatment-resistant depression study (on which Compass Pathways based their business), the world's first LSD, MDMA and DMT brain imaging studies, plus the initiation and collaboration with Johns Hopkins on the first study using psilocybin-assisted psychotherapy to overcome nicotine addiction. She has also co-authored over 80 research papers. Since 1998, the Beckley Foundation has been at the forefront of exploratory research into psychedelics, and evidence-based global drug policies. Through her work with the Beckley Foundation, Amanda is bridging the gap between science and policy, creating a positive feedback loop, with the aim of building and harnessing our knowledge of the benefits of currently prohibited compounds to optimize human health, wellbeing and potential.Today, however, she joins me to discuss how psychedelics have influenced her own journey – taking us from her early days as an independent youth, through her life as an influential spokesperson, advocate, and researcher into psychedelics and non-ordinary states of consciousness.

George Goldsmith, Chairman, CEO and Co-founder of COMPASS Pathways introduces our new podcast series. We are facing a global mental health care crisis and the COVID-19 pandemic has only exacerbated this. Mental health care today works for some people but is not good enough for far too many. And yet there is still a stigma around talking about mental health. But when it comes to mental health, everyone has a story - whether that's about themselves, a family member, a friend or colleague. In this podcast series, we're going to speak to people about their mental health stories. We want to talk about the issues in mental health care and explore how we can improve the patient experience and ease suffering. Our first guests include Sir Norman Lamb – mental health campaigner and Chair of South London and Maudsley NHS Foundation Trust in the UK, and Jewel - singer-songwriter and mental health advocate. We hope to inspire, inform and provoke discussion, as our guests share their stories and ideas. Please do follow us on your favourite podcast app to ensure you don't miss episode one.

Alexander and I unfurl through a fascinating forest of ideas. We track the evolution of Rebel Wisdoms development and outline its spiral like journey from embodiment and liminality to its focus on the impact of Jordan Peterson, its exploration of the Intellectual Dark & Deep Web before a return to its roots. We dance with the knotty but humming question of how to cultivate meaningful culture and community within the context of the digital sense making scene and explore the importance of remembering that we're all in this together, that we're practicing for each other. Ali also gives us an update on how he's feeling about the state of the Psychedelic renaissance after his recent debate with the co-founder of Compass Pathways which is one of the best funded and more Game A companies racing towards the Mushroomy Pot Of Gold at the end of the research rainbow. I feel there is a lot to savour in this exchange, I hope you enjoy it as much as I did. https://rebelwisdom.co.uk/

Together with Professor David Nutt they will be talking about the beauty behind psychoactive substances as well as the, equally interesting, stories from Lady Feilding's life journey. Drug Science live podcast recording with Professor David Nutt!  If you want to find out how to travel to Ceylon for 25 pounds do have a listen! Amanda Feilding is the Founder and Executive Director of the Beckley Foundation, and is widely recognised as a leading force behind the current Psychedelic Renaissance. By establishing key Research Programmes at some of the world's most prestigious institutions (including Imperial College London, Maastricht University, Sant Pau in Barcelona, IDOR and UFRN in Brazil), she has propelled the field forward over the last 20+ years, conducting landmark studies, such as the world's first psilocybin for treatment-resistant depression study (on which Compass Pathways based their business), the world's first LSD, MDMA and DMT brain imaging studies, plus the initiation and collaboration with Johns Hopkins on the first study using psilocybin-assisted psychotherapy to overcome nicotine addiction. She has also co-authored over 80 research papers.Since its inception in 1998, the Beckley Foundation has been at the forefront of exploratory research into psychedelics and cannabis, and evidence-based global drug policies. Through a series of pivotal international seminars at the House of Lords (starting in 2000) with leading figures from around the world in different fields, from science to politics, plus over 60 much-cited books, reports and papers, and numerous meetings with thought-leaders, academics, and policy-makers at the UN and governments around the world, Amanda has ensured that the Beckley Foundation has been at the forefront of global drug policy reform, particularly in the field of cannabis and the psychedelics. Through her work with the Beckley Foundation, Amanda is bridging the gap between science and policy, creating a positive feedback loop, with the aim of building and harnessing our knowledge of the benefits of currently prohibited compounds to optimise human health, wellbeing and potential. Drug Science live podcast recording with Professor David Nutt! CannabisLSDTimothy LearyBart HughesPsychedelic Microdosing LSD's impact on brain interconnectivity Beckley FoundationMdmaJoseph “Joey” MellenAlbert HofmannSir Colin BlakemorePsilocybinThe Beckley/Imperial Psychedelic Research Programme The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteersAlexander “Sasha” ShulginAyahuascaDefault mode networkBrain-derived neurotrophic factor (BDNF)Neuroplasticity ★ Support this podcast ★

Ever wondered how psychedelics can change your life? Or are you just curious to learn more about how psychedelics can be a gateway into expanded consciousness, healing, and more? In this week's episode, I interview my friend and guest, Dina Burkitbayeva who is a serial entrepreneur and investor in the mental health space. Her fund's (Forward Vision Fund) investments include ATAI Life Sciences, COMPASS Pathways, The Third Wave among others. Dina is very passionate about supporting companies and institutions building alternative solutions to mental health and helping promote the message that there are more ways to treat mental health than just medication and talk therapy. Dina runs an investment syndicate on Angelist focused on pre-seed and seed companies in the alternative mental health and higher consciousness companies. She also runs a newsletter focused on latest news and trends in the investment and business aspects of the psychedelics therapeutic space. In this conversation, we cover the following: 1. What are psychedelics? 2. The most widely used psychedelics like Psilocybin, Ayahuasca, ibogaine and Ketamine 3. Why have they become so popular and which companies to look out for in this space 4. How can they be used to heal mental health and specifically anxiety and depression 5. How you can invest in this space 6. Stories of healing from people who have used them when nothing else worked Follow @Gateways_To_Awakening On Instagram if you'd like to stay connected. I'd love to hear from you and learn more about what topics you'd like to learn about, and which shows and topics you enjoyed the most!